{"text": "Study assessments .After study therapy discontinuation , responding or stable patients were required to have follow - up efficacy assessments approximately every 6 weeks ( \u00b11 week ) until documented disease progression , death , or study closure , whichever occurred first .", "label": "", "metadata": {}, "score": "33.091316"}
{"text": "Separate phase II studies with VI in asthma support administration of 25 \u00b5g once daily .Patients and methods .Patients .Patients had to stop their current ICS plus additional controller medication , where applicable , from the morning of Visit 2 ( baseline ) .", "label": "", "metadata": {}, "score": "34.532906"}
{"text": "An 8-week treatment period was selected as an appropriate duration to observe changes in pulmonary function from baseline and to permit assessment of differences between treatments .", "label": "", "metadata": {}, "score": "35.004368"}
{"text": "Treatment phase ( course 1 ) : Patients receive oral CC-4047 once daily on days 1 - 21 followed by a 7-day recovery period .", "label": "", "metadata": {}, "score": "35.842056"}
{"text": "The patients recorded asthma symptom scores ( 0 - 5 ) and rescue salbutamol intake twice daily on a diary card .The investigator evaluated the occurrence of asthma exacerbations at all post - baseline visits upon reviewing the diary card with the patient , with extensive inquiry if needed .", "label": "", "metadata": {}, "score": "36.204063"}
{"text": "Maintenance therapy commenced on Day 1 of the fifth cycle and continued until disease progression , unacceptable toxicity , or another permitted reason for discontinuation .", "label": "", "metadata": {}, "score": "36.2743"}
{"text": "Clinical laboratory and vital signs were assessed during screening , at pre - dose on Day 1 , and before the allergen challenge on Day 29 of each treatment period .", "label": "", "metadata": {}, "score": "38.253365"}
{"text": "There were no pemetrexed dose reductions required during the maintenance phase , but 3 ( 10.7 % ) patients required a pemetrexed dose delay for 1 cycle and 1 ( 3.6 % ) patient had 2 delayed cycles .", "label": "", "metadata": {}, "score": "38.37025"}
{"text": "Patients who develop a DLT during course 1 may continue study treatment at the discretion of the investigator .Extension phase : Patients continue taking CC-4047 at their assigned cohort dose as in course 1 .", "label": "", "metadata": {}, "score": "38.482983"}
{"text": "On average , rescue medication was used less than one day per week in both groups during the treatment phase .Mean number of days / week that rescue medication was used during the run - in and treatment periods ( raw means ) .", "label": "", "metadata": {}, "score": "38.873436"}
{"text": "At the moderate and high doses required to treat some patients with asthma , ICS therapy can lead to suppression of the HPA axis [ 32 ] and it has been suggested that this effect may be accentuated by once - daily dosing in the evening [ 33 , 34 ] .", "label": "", "metadata": {}, "score": "39.114296"}
{"text": "The ICS dosage was optimized and stabilized during the screening period , maintained unchanged throughout the steroid - stable treatment period , and was reduced in subjects with clinically stable asthma during the steroid - reduction treatment period .", "label": "", "metadata": {}, "score": "39.271126"}
{"text": "A key consideration for maintenance therapy is to utilize a well - tolerated agent with a relatively low risk of serious , cumulative toxicities .In advanced NSCLC , maintenance therapy is typically initiated after 4 - 6 cycles of induction chemotherapy with an active doublet and is continued until disease progresses or unacceptable toxicity is reached .", "label": "", "metadata": {}, "score": "40.07312"}
{"text": "In addition , PFS was calculated for the overall study period ( induction plus maintenance therapy ) measured from the first dose of induction therapy to the date of progression or death .", "label": "", "metadata": {}, "score": "40.199654"}
{"text": "Clinical activity .The ACQ-6 was completed at home on a weekly basis , using an electronic patient - reported outcome device .The occurrence of any asthma exacerbations during the study was recorded by the study physician at each clinic visit .", "label": "", "metadata": {}, "score": "40.33167"}
{"text": "Other studies have shown that regular use of ICS is associated with a reduction in hospitalization or emergency room visits due to asthma [ 30 , 31 ] .", "label": "", "metadata": {}, "score": "40.345825"}
{"text": "A protocol - defined asthma exacerbation was a worsening of asthma requiring treatment with oral or intravenous corticosteroid burst and/or a doubling of the baseline inhaled corticosteroids ( ICS ) dose for at least 3 days .", "label": "", "metadata": {}, "score": "40.356316"}
{"text": "A protocol - defined asthma exacerbation was a worsening of asthma requiring treatment with oral or intravenous corticosteroid burst and/or a doubling of the baseline inhaled corticosteroids ( ICS ) dose for at least 3 days .", "label": "", "metadata": {}, "score": "40.356316"}
{"text": "This reduction is of particular interest because long term treatment with high doses of ICS is associated with significant systemic side effects [ 1 ] .", "label": "", "metadata": {}, "score": "40.497128"}
{"text": "Such a discrepancy is consistent with the findings of the FACET study [ 18 ] .Finally , these changes were detected in both groups and are unlikely to be due to a lower compliance , as treatment compliance was greater than 90 % during the step - down phase .", "label": "", "metadata": {}, "score": "40.96286"}
{"text": "Patients were also asked to record in their eDiary their use of non - study issued maintenance ICS during the screening period and their use of blinded study medication to assess compliance with study medication .", "label": "", "metadata": {}, "score": "41.23635"}
{"text": "Number of Participants Experiencing One or More Protocol - defined Asthma Exacerbations During the Treatment Period [ Time Frame : Start of treatment to 24 weeks ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "41.770996"}
{"text": "Discussion .The median PFS times for the maintenance phase did not differ between the two treatment arms .Although clinical researchers may be more familiar with median survival in comparing two treatment groups , this single median point comparison could be insufficient .", "label": "", "metadata": {}, "score": "41.82"}
{"text": "Twenty - four hour urinary - free cortisol excretion was also measured at baseline ( week 0 ) and at the end of the double - blind treatment period ( week 8) to assess hypothalamic - pituitary - adrenal axis ( HPA ) function .", "label": "", "metadata": {}, "score": "42.007156"}
{"text": "That this protection is provided at the trough of dosing , i.e. 23 h post last dose , supports the utility of FF 100 and FF / VI 100/25 as viable once - daily therapies .", "label": "", "metadata": {}, "score": "42.21104"}
{"text": "Our results suggest that clinical decisions should also consider changes occurring after a prolonged period of observation ( 6 months ) .This study is also the first to demonstrate that patients with controlled asthma can maintain control if switched from DPI to pMDI devices while stepping down treatment .", "label": "", "metadata": {}, "score": "42.335503"}
{"text": "Treatment compliance was derived from the number of positive answers in the patient 's eDiary , which were divided by the number of non - missing answers and expressed as a percentage for both morning and evening doses .", "label": "", "metadata": {}, "score": "42.381084"}
{"text": "Percentage of Patients Requiring Rescue Therapy During Main 24-Week Period [ Time Frame : Baseline up to Week 24 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "42.751667"}
{"text": "Courses repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity .Patients undergo blood collection at baseline and periodically during study to evaluate fetal hemoglobin levels .", "label": "", "metadata": {}, "score": "42.92384"}
{"text": "Of the 106 patients that initiated induction therapy , 79 ( 74.5 % ) patients completed 3 cycles of induction therapy and 67 ( 63.2 % ) patients completed 4 cycles of induction therapy .", "label": "", "metadata": {}, "score": "43.096096"}
{"text": "To provide a more comprehensive assessment of the therapeutic benefit of pemetrexed maintenance therapy , quality of life was also examined .In a recently published trial , the results of the quality assessment of these patients were disclosed .", "label": "", "metadata": {}, "score": "43.09613"}
{"text": "However , a lower daily dose of FP for 52 weeks would have been a ' step down ' for the majority of patients who had more severe asthma .", "label": "", "metadata": {}, "score": "43.28341"}
{"text": "The AQLQ(S ) was completed every 4 weeks at home using the electronic patient - reported outcome device .Safety profile .Details of any adverse events ( AEs ) and SAEs were recorded .", "label": "", "metadata": {}, "score": "43.296272"}
{"text": "Preliminary clinical studies in healthy adults and subjects with mild or mild - to - moderate asthma have demonstrated that MEDI-528 administered subcutaneously has linear pharmacokinetics and an acceptable safety profile with no reports of serious adverse events ( SAEs ) [ 11 , 12 ] .", "label": "", "metadata": {}, "score": "43.35789"}
{"text": "In addition , both the induction therapy and maintenance pemetrexed therapy were generally well - tolerated and there were relatively few grade 3/4 TEAEs observed in either study phase .", "label": "", "metadata": {}, "score": "43.49346"}
{"text": "Relatively few studies have evaluated the best strategy for dose reduction [ 7 , 9 - 11 ] .This step - down strategy has the advantage of maintaining asthma control and lowering the dose of ICS [ 7 ] .", "label": "", "metadata": {}, "score": "43.494957"}
{"text": "Treatment groups were well matched with respect to baseline demographics , exacerbation history ( previous 12 months ) and screening lung function ( table 1 ) .", "label": "", "metadata": {}, "score": "43.84301"}
{"text": "Twenty - four hour coverage might be expected to provide greater asthma control ; however , the complexity of asthma treatment regimens and consequent poor adherence to treatment have been cited as major contributing factors to the current poor level of global asthma control [ 2 , 9 , 10 ] .", "label": "", "metadata": {}, "score": "44.082794"}
{"text": "Use of systemic glucocorticoids ( excluding topical application or inhaled forms ) for one week or more within 3 months prior to the time of screening .", "label": "", "metadata": {}, "score": "44.293457"}
{"text": "Patients were observed by appropriately trained site personnel during each clinic visit to ensure that they were able to administer the study drug correctly .The eDiary was used to question patients on their compliance with study medication each morning and evening ; patients who were not compliant were counselled on the appropriate way to administer the study drug .", "label": "", "metadata": {}, "score": "44.34984"}
{"text": "Patients who complete the 24-week main double - blind treatment would undergo a variable double - blind extension treatment , which ends for all patients at approximately the scheduled date of Week 76 visit ( Visit 25 ) for the last randomized patients .", "label": "", "metadata": {}, "score": "44.531757"}
{"text": "Asthma control was maintained in almost all of the patients throughout the 6-month step - down period , with the percentage of controlled plus partly controlled patients always remaining above 93 % in both groups ( Figure 4 ) .", "label": "", "metadata": {}, "score": "44.811226"}
{"text": "The one - year survival probabilities were similar for the two treatment arms for the maintenance phase ( pemetrexed / BSC , 54.4 % ; BSC , 49.5 % ) and the overall study period ( pemetrexed / BSC , 58.6 % ; BSC , 57.8 % ) .", "label": "", "metadata": {}, "score": "44.96223"}
{"text": "Therefore , 106 patients were enrolled and received at least 1 dose of induction therapy .All of the patients in the pemetrexed / BSC arm received at least 1 dose of maintenance therapy .", "label": "", "metadata": {}, "score": "45.081425"}
{"text": "All patients provided written informed consent , and the study was approved by local institutional review boards and regulatory authorities , as appropriate .Outcome measures .", "label": "", "metadata": {}, "score": "45.225723"}
{"text": "No active infection .No uncontrolled hyper- or hypocalcemia , glycosemia , or thyroidism .PRIOR CONCURRENT THERAPY : .No prior CC-4047 .More than 28 days since prior cytotoxic chemotherapy ( 42 days for nitrosoureas ) .", "label": "", "metadata": {}, "score": "45.353497"}
{"text": "Asthma exacerbations and adverse events .Sixty - eight of the 440 patients that were evaluated for safety experienced asthma exacerbations during the 6-month treatment period .", "label": "", "metadata": {}, "score": "45.63401"}
{"text": "The proportion of patients with no asthma symptoms throughout the 6-month step - down phase was 42 % and 40 % for daytime symptoms and 66.3 % and 63.7 % for night - time symptoms in the BDP / F and FP / S groups , respectively .", "label": "", "metadata": {}, "score": "45.686943"}
{"text": "The one - year survival probabilities were similar for both arms for the maintenance phase and the overall study period .Both the induction and continuation maintenance therapies were generally well - tolerated , and similar proportion of patients in each arm experienced at least 1 grade 3/4 TEAE ( pemetrexed / BSC , 17.9 % ; BSC , 18.5 % ) .", "label": "", "metadata": {}, "score": "45.791298"}
{"text": "Progression - free survival and overall survival .The median PFS time for the maintenance phase for both treatment arms was 3.2 months ( pemetrexed / BSC arm , 95 % CI : 2.9 to 6.1 ; BSC arm , 95 % CI : 2.2 to 4.3 ) .", "label": "", "metadata": {}, "score": "45.92192"}
{"text": "Patients were excluded from the study if they had been hospitalized for a COPD exacerbation in the 6 weeks prior to screening or during the run - in period ; had a history of asthma ; or had concomitant pulmonary disease or a significant unstable cardiovascular or metabolic comorbidity .", "label": "", "metadata": {}, "score": "46.35077"}
{"text": "Published literature suggests that regular therapy with ICS can reduce the early asthmatic response ( EAR ) [ 13 , 14 ] though this has not been consistently observed [ 10 ] suggesting a need for improved therapies .", "label": "", "metadata": {}, "score": "46.50506"}
{"text": "Five of the 11 patients reporting an on - treatment SAE were withdrawn from the study due to the SAE .No deaths were reported during the study .", "label": "", "metadata": {}, "score": "46.54226"}
{"text": "Have received chronic systemic corticosteroids ( oral or intravenous ) within 3 months or have received a burst of oral corticosteroids within the last 2 weeks prior to screening .", "label": "", "metadata": {}, "score": "46.588367"}
{"text": "Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia [ Time Frame : First dose of study drug up to 3 days after the last dose administration ] [ Designated as safety issue : Yes ] .", "label": "", "metadata": {}, "score": "46.60928"}
{"text": "The primary objective of this study was to evaluate the effect of multiple dose subcutaneous administration of MEDI-528 on symptom control in adults with uncontrolled , moderate - to - severe , persistent asthma .", "label": "", "metadata": {}, "score": "46.837982"}
{"text": "PubMed View Article .Price D , Robertson A , Bullen K , Rand C , Horne R , Staudinger H : Improved adherence with once - daily versus twice - daily dosing of mometasone furoate administered via a dry powder inhaler : a randomized open - label study .", "label": "", "metadata": {}, "score": "46.964226"}
{"text": "PubMed View Article .Brusasco V , Hodder R , Miravitlles M , Korducki L , Towse L , Kesten S : Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD .", "label": "", "metadata": {}, "score": "47.052372"}
{"text": "Concomitant medication .Allowable concurrent COPD therapies included the use of inhaled corticosteroids ( ICS ) , provided the regimen had been stabilized for at least 1 month prior to the screening visit .", "label": "", "metadata": {}, "score": "47.084488"}
{"text": "Clinical activity .Mean ACQ-6 score .Improvements in mean ACQ-6 score occurred in all groups at weeks 13 and 25 , with little difference between placebo and the individual MEDI-528 treatment groups ( Figure 3 ) .", "label": "", "metadata": {}, "score": "47.08738"}
{"text": "Severe exacerbations occurred in 2.4 % and 1.9 % of patients in the FP / S and BDP / F groups , respectively .The mean ( SE ) time to first asthma exacerbation was 154.7 ( 2.3 ) days in the FP / S group and 143.4 ( 2.5 ) days in the BDP / F group .", "label": "", "metadata": {}, "score": "47.094437"}
{"text": "No clinically relevant decreases in potassium or increases in non - fasting glucose were observed .An important strength of this study is the 52-week duration which provides useful information on the longer - term safety and tolerability effects of FF / VI in patients with asthma .", "label": "", "metadata": {}, "score": "47.23465"}
{"text": "Blood and urine samples were collected at screening , prior to the first dose , at 4-weekly intervals during the treatment period , and 8-weekly intervals during the follow - up period for routine clinical laboratory evaluations .", "label": "", "metadata": {}, "score": "47.40866"}
{"text": "Three of the AEs that resulted in discontinuation were considered likely to be related to study medication ( 100 mg , musculoskeletal pain and pain in extremity ; 300 mg , headache ) .", "label": "", "metadata": {}, "score": "47.479652"}
{"text": "Assessments and outcomes .All clinic visits started in the morning .Spirometry was also assessed on Day 2 and Day 15 of each treatment period at 23 h 10 min and 23 h 45 min post - dose ( based on the time of study drug administration on the previous day ) to enable trough values of FEV 1 to be determined .", "label": "", "metadata": {}, "score": "47.60965"}
{"text": "Patients meeting the entry criteria entered a 2-week run - in period for completion of baseline safety evaluations and asthma status measures .FF / VI was administered via a dry powder inhaler ( DPI ) and FP was administered by DISKUS / ACCUHALER .", "label": "", "metadata": {}, "score": "47.706894"}
{"text": "If fasting SMPG value exceeded the specified limit for 3 consecutive days , the central laboratory FPG ( and HbA1c after week 12 ) were performed .", "label": "", "metadata": {}, "score": "47.939262"}
{"text": "Moreover , this is the first study to demonstrate that the majority of patients who are controlled with high dose ICS / LABA DPI can be stepped down to medium dose DPI or extra - fine pMDI combinations and still maintain asthma control .", "label": "", "metadata": {}, "score": "48.0756"}
{"text": "In addition , an intrinsic limitation of our study design is that we could not confirm that patients were on the minimum dose that maintained asthma control before study start .", "label": "", "metadata": {}, "score": "48.10868"}
{"text": "The finding of an optimal maintenance therapy for patients with locally advanced or metastatic non - squamous NSCLC , who achieved disease control after first - line chemotherapy , is still the subject of study .", "label": "", "metadata": {}, "score": "48.51576"}
{"text": "No treatment - related changes were apparent .24-hour UC excretion at week 8 was similar across treatment groups with adjusted geometric means of 48.24 nmol/24 hour for placebo and 43.41 - 57.23 nmol/24 hour for the FF treatment groups .", "label": "", "metadata": {}, "score": "48.75939"}
{"text": "However , patients were selected from pulmonary centres where they were regularly assessed and treated according to the current guidelines , suggesting that the dose of the original ICS / LABA prescription was appropriate .", "label": "", "metadata": {}, "score": "48.860855"}
{"text": "Patients .To be eligible for study entry , subjects were required to be aged 18 - 65 years and to have a documented history of bronchial asthma for at least 6 months , managed with intermittent inhaled short - acting beta - agonist ( SABA ) therapy only .", "label": "", "metadata": {}, "score": "49.048084"}
{"text": "After the discontinuation of study therapy , a similar proportion of patients in each arm received at least one type of additional anticancer therapy ( pemetrexed / BSC , 46.4 % ; BSC , 44.4 % ) .", "label": "", "metadata": {}, "score": "49.158905"}
{"text": "The results of our study showed that continuous pemetrexed maintenance therapy following 4 cycles of pemetrexed - cisplatin induction therapy resulted in promising PFS with an acceptable safety profile in a Middle Eastern population with advanced non - squamous NSCLC , and that it is worthy of further investigation .", "label": "", "metadata": {}, "score": "49.20419"}
{"text": "LABAs have also demonstrated protection in exercise - induced asthma models [ 24 , 25 ] where the challenge was initiated at or near the end of the dosing period , suggesting that functional antagonism can persist throughout the dosing period .", "label": "", "metadata": {}, "score": "49.370163"}
{"text": "Only one ICS ( mometasone furoate ) is currently recommended for once - daily dosing in both the US and Europe but only for use in patients with non - severe asthma [ 2 , 27 ] .", "label": "", "metadata": {}, "score": "49.465874"}
{"text": "A significant decrease in the morning PEF values of the BDP / F group ( 17.3 L / min ) and the FP / S group ( 35.1 L / min ) was detected 6 months after the step - down , with the latter being above the value that is considered clinically relevant [ 17 ] .", "label": "", "metadata": {}, "score": "49.49449"}
{"text": "In addition , the majority of patients had not experienced an asthma exacerbation ( all severities ) in the past 12 months .The number of withdrawals due to an AE was similar across treatment groups ( figure 1 ) .", "label": "", "metadata": {}, "score": "49.512768"}
{"text": "However , the increases in pulse rate were reported only sporadically during the study ( one or two visits only ) .Furthermore , the ECG HR findings observed post dose are consistent with that observed with other inhaled agonists at the \u03b2 - agonist receptor .", "label": "", "metadata": {}, "score": "49.6628"}
{"text": "PubMed View Article .Noonan M , Karpel JP , Bensch GW , Ramsdell JW , Webb DR , Nolop KB , Lutsky BN : Comparison of once - daily to twice - daily treatment with mometasone furoate dry powder inhaler .", "label": "", "metadata": {}, "score": "49.764412"}
{"text": "PubMed View Article .Herjavecz I , Blomqvist P , Serrano A : Efficacy of once- and twice - daily administration of budesonide via Turbuhaler as initial therapy in patients with mild persistent asthma .", "label": "", "metadata": {}, "score": "49.827904"}
{"text": "The safety population included all patients who received at least one dose of study drug .Patients were analyzed according to treatment received .To allow for multiplicity , a Bonferroni adjustment was applied to maintain the overall Type I error rate at 5 % .", "label": "", "metadata": {}, "score": "49.885612"}
{"text": "Nevertheless , the results showed a clear and significant effect on the EAR after 28 days once - daily therapy with either FF 100 or FF / VI 100/25 yielding an approximate 150 mL reduction in the extent of the EAR over the first 2 h post - challenge relative to placebo .", "label": "", "metadata": {}, "score": "50.0152"}
{"text": "The study comprised a pre - screening visit , a 14-day screening period , followed by three 14-day treatment periods , each of which was separated by a 14-day washout .", "label": "", "metadata": {}, "score": "50.061844"}
{"text": "We designed the study according to the preferred option recommended by international guidelines for the step - down procedure for patients under high dose ICS / LABA consisting in reducing the ICS dose while maintaining the LABA [ 1 ] .", "label": "", "metadata": {}, "score": "50.20092"}
{"text": "Subjects .Subjects were either currently taking medium to high - dose inhaled corticosteroids ( ICS ) or were eligible to take them based on Expert Panel Report 3 guidelines , and were started on medium to high - dose ICS at the start of the run - in phase of the study [ 1 ] .", "label": "", "metadata": {}, "score": "50.336884"}
{"text": "This number of patients would give 99 % power for the primary endpoint , assuming a minimum clinically important difference ( MCID ) of 120 mL. All efficacy variables , including the primary efficacy variable , were analyzed for the modified intent - to - treat ( mITT ) population comprising all randomized patients who received at least one dose of study drug .", "label": "", "metadata": {}, "score": "50.447853"}
{"text": "Similarly , ciclesonide 200 mcg once daily dosed in the evening compared with morning dosing resulted in greater improvements in morning ( 12-hour treatment ) and evening ( 24-hour treatment ) PEF relative to baseline at 8 weeks [ 16 ] .", "label": "", "metadata": {}, "score": "50.452934"}
{"text": "Self - administered by subcutaneous injections once daily within the hour preceding breakfast .Device : Pen auto - injector .Metformin to be continued at stable dose ( at least 1.5 gram per day ) up to the end of treatment .", "label": "", "metadata": {}, "score": "50.4557"}
{"text": "Summary statistics for these evaluations are presented in results .In addition , the incidence of treatment - emergent adverse events ( AEs ) was assessed as a secondary endpoint .", "label": "", "metadata": {}, "score": "50.500847"}
{"text": "Treatment with an antidiabetic pharmacological agent other than metformin within the 3 months preceding the screening .Weight change of more than 5 kg during the 3 months preceding the screening visit .", "label": "", "metadata": {}, "score": "50.713947"}
{"text": "Investigators were responsible for providing appropriate BSC .Permitted pemetrexed dose modifications and delays due to certain toxicities were defined in the protocol .Higher or additional dexamethasone doses were permitted for reasons other than routine rash prophylaxis ( e.g. antiemetic prophylaxis ) .", "label": "", "metadata": {}, "score": "50.75605"}
{"text": "Current maintenance therapy for asthma typically comprises an inhaled corticosteroid ( ICS ) , supplemented , where additional control is required , with additional controller medications , the preferred add - on therapy being an inhaled long - acting beta - agonist ( LABA ) .", "label": "", "metadata": {}, "score": "50.76197"}
{"text": "A positive culture was required for oral / oropharyngeal candidiasis to be reported as an AE .Clinical laboratory assessments , including non - fasting glucose , potassium , liver function tests and 24-h urinary cortisol ( UC ) excretion were completed prior to treatment and at Weeks 12 , 28 and 52 or early withdrawal .", "label": "", "metadata": {}, "score": "50.915092"}
{"text": "Over the 3 periods , each subject took 28 days of once - daily inhaled study treatment ( FF 100mcg , FF / VI 100/25mcg or placebo ) via a novel dry - powder inhaler each evening between 6 pm and 8 pm .", "label": "", "metadata": {}, "score": "50.943203"}
{"text": "This approach differs from the majority of allergen - response studies , where the efficacy of treatment is assessed in the challenge model shortly after dosing or at peak drug levels .", "label": "", "metadata": {}, "score": "51.01246"}
{"text": "The secondary outcomes included asthma control and exacerbation frequency .Results .Four hundred twenty - two patients were included in the analysis .The PEF values remained above 95 % of the predicted values throughout the study .", "label": "", "metadata": {}, "score": "51.070534"}
{"text": "The overall safety profile observed with FF / VI did not reveal unusual or unexpected findings of significant clinical concern .Safety findings that were observed reflected the expected pharmacological activity of the ICS and LABA components .", "label": "", "metadata": {}, "score": "51.074455"}
{"text": "( ACQ-6 ) score at week 13 .Secondary endpoints included weighted asthma exacerbation rates and pre - bronchodilator forced expiratory volume in 1 second ( FEV 1 ) at weeks 13 and 25 , as well as Asthma Quality of Life Questionnaire scores at weeks 12 and 25 and the safety of MEDI-528 throughout the study period .", "label": "", "metadata": {}, "score": "51.20984"}
{"text": "The following medications could not be used after the screening visit ( except as study medication ) : long- or short - acting anticholinergic agents , long- or short - acting \u03b2 2 -agonists , xanthine derivatives , and parenteral or oral corticosteroids .", "label": "", "metadata": {}, "score": "51.213615"}
{"text": "No changes from baseline were detected in PEF and forced expiratory volume in 1 second measured at the clinics , in the symptom scores or in the use of rescue medication .", "label": "", "metadata": {}, "score": "51.218338"}
{"text": "The analysis of the time to first asthma exacerbation was performed using the Kaplan - Meier method .Safety was analysed in all of the randomised patients who received at least 1 dose of study medication .", "label": "", "metadata": {}, "score": "51.512474"}
{"text": "Table 3 . a One subject ( 2 % ) had seasonal allergy , reported as allergic rhinitis , during each treatment period .One subject withdrew during the study due to an SAE , which occurred 4 days after the last dose in the FF 100 treatment period .", "label": "", "metadata": {}, "score": "51.538574"}
{"text": "More than 14 days since prior thalidomide , lenalidomide , or structurally related compounds .More than 14 days since prior biological response modifier therapy .", "label": "", "metadata": {}, "score": "51.738453"}
{"text": "During the induction phase , all 106 patients were compliant with the required vitamin B 12 supplementation , and compliance with the required folic acid supplementation ranged from 89.3 - 100.0 % .", "label": "", "metadata": {}, "score": "51.85843"}
{"text": "In a crossover study of 52 subjects with mild asthma , FF / VI 100/25mcg and FF 100 dosed once - daily in the evening for 28 days were compared with placebo to evaluate their capacity to provide bronchoprotection against the early asthmatic response ( EAR ) stimulated by an inhaled allergen challenge .", "label": "", "metadata": {}, "score": "51.90787"}
{"text": "Data from other phase II studies evaluating FF have reported similar safety findings with daily doses of up to 600 mcg [ 20 - 22 ] as those reported here , save for no withdrawals due to oedema .", "label": "", "metadata": {}, "score": "51.919685"}
{"text": "Mean overall compliance ranged from 97.4 - 99.1 % and from 96.6 - 98.4 % for the morning and evening dosing regimens , respectively .Mean exposure to study drug was 43.1 days in the placebo group and ranged from 50.3 - 52.2 days in the FF groups ; exposure was highest in the FF 400 mcg once - daily morning group and lowest in the FF 200 mcg once - daily evening group .", "label": "", "metadata": {}, "score": "51.959812"}
{"text": "As a reflection of this , the current Global Initiative for Asthma guidelines recommend an ICS as a first - line controller therapy for asthma patients of all ages , who are not controlled on an as - needed , rapid acting beta 2 agonist [ 2 ] .", "label": "", "metadata": {}, "score": "51.97364"}
{"text": "Results .In total , 562 patients were screened between April 2007 and July 2009 ( Figure 1 ) .A flow - chart representing patient flow .", "label": "", "metadata": {}, "score": "52.037716"}
{"text": "On Day 29 subjects underwent an inhaled allergen challenge 22 - 23 h after their Day 28 treatment , thus the challenge was initiated between 4 pm and 7 pm .", "label": "", "metadata": {}, "score": "52.101967"}
{"text": "Immunotherapy was permitted if initiated before screening and used at a stable dose for the treatment of allergies .Drug therapies for other medical conditions , with the exception of systemic corticosteroids , were permitted throughout the study provided the dose remained constant and their use was not expected to affect the patient 's lung function or asthma status .", "label": "", "metadata": {}, "score": "52.1259"}
{"text": "Omalizumab ( Xolair ) was administered subcutaneously every 2 or 4 weeks .The dose ( mg ) and dosing frequency were determined by serum total IgE level ( IU / mL ) , measured before the start of treatment , and body weight ( kg ) .", "label": "", "metadata": {}, "score": "52.257088"}
{"text": "PubMed View Article .Boulet LP : Once - daily inhaled corticosteroids for the treatment of asthma .Curr Opin Pulm Med 2004 , 10 : 15 - 21 .", "label": "", "metadata": {}, "score": "52.271847"}
{"text": "Abstract .Background .Asthma guidelines suggest that therapy can be reduced once asthma is controlled .Despite these recommendations , asthmatic patients are seldom stepped down in clinical practice , and questions remain about when and how to reduce asthma therapy .", "label": "", "metadata": {}, "score": "52.307037"}
{"text": "The questions that need to be addressed include whether a step - down of controller medication can be achieved without a loss of lung function and asthma control .", "label": "", "metadata": {}, "score": "52.337036"}
{"text": "All of the authors had full access to all of the data in the study and assume final responsibility for the decision to submit the study for publication .", "label": "", "metadata": {}, "score": "52.360336"}
{"text": "In conclusion , FF 100 and FF / VI 100/25 - doses that have been progressed to phase III trials - inhaled daily over 28 days provide significant and clinically relevant bronchoprotection against the EAR relative to placebo .", "label": "", "metadata": {}, "score": "52.418114"}
{"text": "Consequent to this , one subject reported two occurrences of seasonal allergy as an AE during the FF 100 treatment period , on days 2 and 23 .", "label": "", "metadata": {}, "score": "52.45425"}
{"text": "Three patients ( 1 % ) on FF / VI 100/25 \u00b5g , six ( 3 % ) on FF / VI 200/25 \u00b5g and three ( 3 % ) on FP experienced a severe exacerbation during the treatment period .", "label": "", "metadata": {}, "score": "52.47613"}
{"text": "On completion of the screening period , eligible patients were randomized using a validated automated system to receive three of the four treatments ( with a different treatment in each treatment period ) , each once - daily .", "label": "", "metadata": {}, "score": "52.513016"}
{"text": "The patients used a portable flow meter ( Piko-1 , Ferraris Louisville , CO , USA ) in compliance with ATS standard 2004 to measure their morning and evening PEF values prior to the study drug intake and 6 hours from the previous salbutamol dose .", "label": "", "metadata": {}, "score": "52.529224"}
{"text": "Statistical analyses were performed for 24-h UC , HR , QTc(F ) , blood pressure and pulse rate .The relative safety of each FF / VI dose was evaluated by assessing the confidence intervals for the treatment differences compared with the marketed benchmark , FP 500 \u00b5g twice daily for these endpoints and p values were provided for descriptive purposes .", "label": "", "metadata": {}, "score": "52.68155"}
{"text": "Methods .In this prospective double - blind , multicenter , parallel - group study , 329 subjects were randomized ( 1:1:1:1 ) to subcutaneous placebo or MEDI-528 ( 30 , 100 , 300 mg ) every 2 weeks for 24 weeks , in addition to their usual asthma medications .", "label": "", "metadata": {}, "score": "52.93827"}
{"text": "OS for the maintenance phase was calculated from randomization to death from any cause .OS for the overall study period was calculated from the first dose of induction therapy to death from any cause .", "label": "", "metadata": {}, "score": "52.9457"}
{"text": "Determine the maximum tolerated dose of CC-4047 in patients with advanced refractory solid tumors .Secondary .Determine the effect of this drug on fetal hemoglobin levels in these patients .", "label": "", "metadata": {}, "score": "52.958046"}
{"text": "One study showed no difference in placebo - adjusted 24-hour UC results for budesonide 400 mcg administered once daily in the morning compared with evening [ 35 ] .", "label": "", "metadata": {}, "score": "53.013603"}
{"text": "PubMed View Article .Casaburi R , Briggs DD Jr , Donohue JF , Serby CW , Menjoge SS , Witek TJ Jr : The spirometric efficacy of once - daily dosing with tiotropium in stable COPD : a 13-week multicenter trial .", "label": "", "metadata": {}, "score": "53.140533"}
{"text": "Any previous treatment with lixisenatide or participation in any previous study with lixisenatide .Clinically relevant history of gastrointestinal disease associated with prolonged nausea and vomiting , including , but not limited to gastroparesis and gastroesophageal reflux disease requiring medical treatment , within 6 months prior to the time of screening .", "label": "", "metadata": {}, "score": "53.340034"}
{"text": "b The most common TEAEs during induction and maintenance therapy in the patients randomized to the maintenance phase arms .c Considered to be study drug - related .", "label": "", "metadata": {}, "score": "53.360313"}
{"text": "Demographic and clinical baseline characteristics of all randomized patients with non - squamous NSCLC ( maintenance phase a ) .Note : The sum of percentages for some characteristics do not add up to 100 % due to rounding .", "label": "", "metadata": {}, "score": "53.38679"}
{"text": "However , COPD remains a chronic disabling condition and additional therapeutic options are needed to achieve optimal disease management .Furthermore , patients ' compliance with treatment could be improved if regimens are simplified by reducing the dosing frequency - especially given that the high incidence of comorbidities means that many patients with COPD require polypharmacy [ 10 ] .", "label": "", "metadata": {}, "score": "53.445732"}
{"text": "ISBC provided the patient with the prepared study drug and devices and monitored administration of the drug by patients and also ensured that the blinding was maintained throughout .", "label": "", "metadata": {}, "score": "53.497875"}
{"text": "Treatment compliance was very high throughout the study ( including inter - visit assessments ) , suggesting that changes in patients ' level of compliance to FP study medication during the study is an unlikely reason for the UC excretion observations reported with FP at Weeks 12 , 28 and 52 .", "label": "", "metadata": {}, "score": "53.595093"}
{"text": "Data from an early phase clinical study demonstrated that the duration of action of FF extends beyond 24 hours and is therefore longer than that of FP , making FF potentially suitable for consideration of once - daily administration [ 19 ] .", "label": "", "metadata": {}, "score": "53.64358"}
{"text": "The proportions of patients that experienced TEAEs during the maintenance phase were relatively low , and the observed toxicities for the pemetrexed / BSC arm were mostly mild to moderate ( grade 1 or 2 ) and not unexpected for pemetrexed monotherapy .", "label": "", "metadata": {}, "score": "53.660233"}
{"text": "Therefore , the disease control rate for the induction phase was 71.7 % ( 76/106 ) .For the maintenance phase , there were no cases of a best response of CR or PR , thus the overall response rate was 0.0 % for both arms .", "label": "", "metadata": {}, "score": "53.66366"}
{"text": "Extensive study - specific ophthalmic examinations reported no apparent effects with FF / VI or FP .There was little change from baseline in UC excretion in any treatment group .", "label": "", "metadata": {}, "score": "53.665382"}
{"text": "The subject in the MEDI-528 group who experienced an exacerbation received the lowest dose ( 0.3 mg / kg ) , which indicated that it was not due to a dose effect .", "label": "", "metadata": {}, "score": "53.689133"}
{"text": "Although asthma guidelines advocate reducing treatment once asthma is well controlled [ 1 , 6 ] , clinicians appear to be reluctant to reduce treatment .", "label": "", "metadata": {}, "score": "53.77183"}
{"text": "The values that were measured in the randomisation visit ( end of the run - in ) were considered baseline values for the variables measured at the clinics .", "label": "", "metadata": {}, "score": "53.861774"}
{"text": "All 4 patients required hospitalization for their SAEs ; however , only the case of angioedema was considered to be possibly related to the study drug .", "label": "", "metadata": {}, "score": "53.898438"}
{"text": "Study treatment .After completing the screening assessments , eligible patients commenced first - line , induction chemotherapy with pemetrexed and cisplatin .Pemetrexed ( 500 mg / m 2 ) and cisplatin ( 75 mg / m 2 ) were given intravenously on Day 1 of each 21-day cycle up to a maximum of 4 cycles or until disease progression , unacceptable toxicity , or another permitted reason for discontinuation .", "label": "", "metadata": {}, "score": "53.93193"}
{"text": "Scores were collected daily .Change from Baseline ( mean of last 28 days prior to first dosing date ) at Week 24 ( mean of last 28 days prior to week 24 visit ) .", "label": "", "metadata": {}, "score": "53.95211"}
{"text": "These results are consistent with those observed in long - term studies [ 16 , 17 , 22 ] , which also confirm that there is no loss in efficacy with once - daily dosing of indacaterol for up to a year .", "label": "", "metadata": {}, "score": "54.19667"}
{"text": "In each of these studies no difference was seen between once daily morning or evening administration in terms of AEs [ 13 ] , including cortisol levels where assessed [ 15 , 16 ] .", "label": "", "metadata": {}, "score": "54.240314"}
{"text": "No difference in the morning PEF , asthma control , exacerbation rates and lung function measured at clinics was found between the FP / S combination and the extrafine BDP / F pMDI .", "label": "", "metadata": {}, "score": "54.299286"}
{"text": "Summary of the time course of maximum percentage change in post - saline baseline FEV 1 .Therapy was dosed between 6 pm and 8 pm on Days 1 - 28 and the allergen challenge initiated on Day 29 ( between 4 pm and 7 pm ) .", "label": "", "metadata": {}, "score": "54.323845"}
{"text": "Continuation pemetrexed maintenance therapy resulted in promising PFS with an acceptable safety profile in a Middle Eastern population with advanced non - squamous NSCLC and is worthy of further investigation .", "label": "", "metadata": {}, "score": "54.327415"}
{"text": "PubMed View Article .Postma DS , Sevette C , Martinat Y , Schl\u00f6sser N , Aumann J , Kaf\u00e9 H : Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening .", "label": "", "metadata": {}, "score": "54.344566"}
{"text": "Reinberg A , Smolensky MH , D'Alonzo GE , McGovern JP : Chronobiology and asthma III .Timing corticotherapy to biological rhythms to optimize treatment goals .", "label": "", "metadata": {}, "score": "54.36393"}
{"text": "However , in the current study , no significant differences in the asthma exacerbation rate occurred between placebo and MEDI-528 in adults with uncontrolled moderate - to - severe persistent asthma .", "label": "", "metadata": {}, "score": "54.42183"}
{"text": "Non adherence to treatment is an important issue in asthma management , particularly in patients on long - term ICS and other controller medications [ 2 , 28 ] .", "label": "", "metadata": {}, "score": "54.42797"}
{"text": "Other efficacy variables included trough FEV 1 after the first dose , and FEV 1 measurements at individual timepoints after the first dose and on Day 14 in each treatment period .", "label": "", "metadata": {}, "score": "54.42863"}
{"text": "To date , no studies have assessed a treatment step - down to different drug combinations that are delivered by different inhaler devices ( dry powder and pressurised metered dose inhalers ) .", "label": "", "metadata": {}, "score": "54.434162"}
{"text": "For the Q - ITT and TA populations , patients were analyzed according to the therapy to which they were randomly assigned .Safety analyses were conducted with the safety analysis population , which included all patients who received at least one dose of study therapy .", "label": "", "metadata": {}, "score": "54.43768"}
{"text": "Objective To assess the safety and tolerability of FF / VI over 52 weeks in patients with asthma .Safety evaluations included adverse events ( AEs ) , non - fasting glucose , potassium , 24-h urinary cortisol excretion , ophthalmic assessments , heart rate and pulse rate .", "label": "", "metadata": {}, "score": "54.456894"}
{"text": "Obviously , we can not rule out this possibility .However , as this is a phase 2 proof of concept study rather than a confirmatory phase 3 trial , an independent review panel was not used to validate the investigator assessments .", "label": "", "metadata": {}, "score": "54.47783"}
{"text": "Serious AE occurred in 1.4 % and 0.5 % of patients in the FP / S and BDP / F groups , respectively .Discussion .", "label": "", "metadata": {}, "score": "54.491966"}
{"text": "Trial registration .Keywords . once - daily ICS asthma .Background .Despite the availability of effective preventative therapies , asthma remains a major global healthcare problem , placing a significant burden on healthcare systems , patients and their families [ 1 , 2 ] .", "label": "", "metadata": {}, "score": "54.500664"}
{"text": "The results from this 52-week study of FF / VI in adolescents and adults with asthma showed that FF / VI 100/25 \u00b5g or 200/25 \u00b5g , dosed once daily in the evening , was well tolerated .", "label": "", "metadata": {}, "score": "54.590027"}
{"text": "Unspecified Adult Solid Tumor , Protocol Specific .Intervention ICMJE .Drug : CC-4047 .Oral CC-4047 once daily on days 1 - 21 followed by a 7-day recovery period .", "label": "", "metadata": {}, "score": "54.665077"}
{"text": "View Article .Jones AH , Langdon CG , Lee PS , Lingham SA , Nankani JP , Follows RM , Tollemar U , Richardson PD : Pulmicort Turbohaler once daily as initial prophylactic therapy for asthma .", "label": "", "metadata": {}, "score": "54.670303"}
{"text": "Table 3 .A total of four SAEs were reported .Two of these occurred on treatment and included one case of angioedema in the FF 200 mcg once - daily evening group and one case of atrial fibrillation in the FF 400 mcg once - daily morning group .", "label": "", "metadata": {}, "score": "54.68534"}
{"text": "Adverse events ( AEs ) and serious AEs were recorded , along with their severity , duration and relationship to study drug .Other safety assessments included : urinalysis ; regular monitoring of hematology , blood chemistry ( including serum potassium and blood glucose ) and vital signs ; and assessment of corrected QT interval ( QTc ) .", "label": "", "metadata": {}, "score": "54.74025"}
{"text": "The analysis was performed separately for morning and evening time - points , with the placebo and twice - daily regimens used in both cases .", "label": "", "metadata": {}, "score": "54.819122"}
{"text": "HR has been commonly used to present the primary result of survival data in oncology trials .Disease control rates , OS and one - year survival probabilities for the maintenance phase were similar for both arms .", "label": "", "metadata": {}, "score": "54.85344"}
{"text": "Although not formally evaluated in this study , such a ' step - up ' in treatment may account , at least in part , for the observed excretion ratios to baseline with FP observed at Weeks 12 and 28 in this study .", "label": "", "metadata": {}, "score": "54.881"}
{"text": "The presence or absence of the LAR was not determined .On Day 29 of each treatment period , subjects underwent inhaled allergen challenges 22 - 23 h ( between 4 pm and 7 pm ) after their Day 28 treatment using a bolus dose of allergen , which was calculated by totalling all the allergen administered during the screening allergen challenge .", "label": "", "metadata": {}, "score": "54.975864"}
{"text": "Consequently both have the potential to reduce the symptoms associated with the allergic response in atopic asthma subjects , and to improve asthma control and quality of life .", "label": "", "metadata": {}, "score": "55.00719"}
{"text": "The study initially required a total of 44 randomized patients to have 80 % power to detect a true treatment effect of 0.56 at a one - sided alpha of 0.2 , in which case pemetrexed continuation maintenance therapy would be considered to warrant further investigation .", "label": "", "metadata": {}, "score": "55.03035"}
{"text": "The design of the current study utilized pre - dose FEV 1 as the primary endpoint because it is a reliable index of 24-hour duration of action and the study was adequately powered to demonstrate treatment differences on this basis .", "label": "", "metadata": {}, "score": "55.121452"}
{"text": "In other words , we used a RCT to test if the high ICS doses utilised to maintain asthma control in real life conditions can be safely stepped down .", "label": "", "metadata": {}, "score": "55.34424"}
{"text": "PubMed View Article .Koenig SM , Ostrom N , Pearlman D , Waitkus - Edwards K , Yancey S , Prillaman BA , Dorinsky P : Deterioration in asthma control when subjects receiving fluticasone propionate / salmeterol 100/50 mcg Diskus are \" stepped - down \" .", "label": "", "metadata": {}, "score": "55.450497"}
{"text": "Have a history of upper respiratory infection or lower respiratory infection within the 30 days prior to randomization .Have a diagnosis of aspirin or nonsteroidal anti - inflammatory drug - induced asthma .", "label": "", "metadata": {}, "score": "55.47713"}
{"text": "PubMed View Article .Eur Respir J 2005 , 26 : 319 - 338 .PubMed View Article .Giraud V , Rogeaux Y , Dusser D : Asthma control following initial inhaled corticosteroid monotherapy in mild to moderate asthma : a 4- to 8-week observational study .", "label": "", "metadata": {}, "score": "55.54573"}
{"text": "Friedman HS , Navaratnam P , McLaughlin J : Adherence and asthma control with mometasone furoate versus fluticasone propionate in adolescents and young adults with mild asthma .", "label": "", "metadata": {}, "score": "55.63778"}
{"text": "Change was calculated by subtracting baseline value from Week 24 value .For a patient to be included in mITT population , both baseline and at least 1 post baseline assessment for at least 1 efficacy variable , were required .", "label": "", "metadata": {}, "score": "55.6819"}
{"text": "Change was calculated by subtracting baseline value from Week 24 value .For a patient to be included in mITT population , both baseline and at least 1 post baseline assessment for at least 1 efficacy variable , were required .", "label": "", "metadata": {}, "score": "55.6819"}
{"text": "Inhaled corticosteroids ( ICS ) represent the cornerstone of maintenance treatment .If asthma control is inadequate with low - dose ICS , the addition of a long - acting \u03b22-agonist ( LABA ) provides enhanced clinical benefits compared to increasing the ICS dosage [ 2 - 4 ] .", "label": "", "metadata": {}, "score": "55.70545"}
{"text": "During the double - blind treatment phase , patients were required to attend 5 on - treatment morning clinic visits ( weeks 1 , 2 , 4 , 6 , and 8) and 3 on - treatment evening clinic visits ( weeks 2 , 4 , and 8) .", "label": "", "metadata": {}, "score": "55.761627"}
{"text": "However , FP 500 \u00b5g twice daily is associated with more steroid - associated AEs than lower FP doses 13 - 15 and this dose of FP was therefore selected in our study as a benchmark to which FF / VI safety data could be compared .", "label": "", "metadata": {}, "score": "55.89442"}
{"text": "No other concurrent chemotherapy or immunotherapy .No other concurrent investigational agents .No concurrent hematopoietic growth factors during the treatment phase of the study .", "label": "", "metadata": {}, "score": "56.072945"}
{"text": "Change from baseline ( week 0 ) in mean ACQ-6 score at weeks 13 ( primary endpoint ) and 25 was analyzed using an analysis of covariance model .", "label": "", "metadata": {}, "score": "56.10161"}
{"text": "Two subjects were withdrawn from the study , one due to a SAE during the FF 100 treatment washout ; and one subject withdrew consent during the FF / VI 100/25 treatment period .", "label": "", "metadata": {}, "score": "56.103775"}
{"text": "PubMed View Article .Kosoglou T , Cutler DL , Staudinger H , Herron JM : Once - daily evening dosing of mometasone furoate administered via a dry powder inhaler does not adversely affect the hypothalamic - pituitary - adrenal axis .", "label": "", "metadata": {}, "score": "56.14737"}
{"text": "In addition , stratified PFS was prospectively determined as the primary endpoint of the trial to minimize potential confounding from differences in response to induction therapy .", "label": "", "metadata": {}, "score": "56.18164"}
{"text": "We intentionally selected patients whose asthma was controlled under the highest recommended dose of the FP / S combination , which is the most prescribed therapy for obstructive lung diseases in Europe [ 21 ] .", "label": "", "metadata": {}, "score": "56.2428"}
{"text": "Safety .During the induction phase , 73 ( 68.9 % ) patients experienced at least 1 treatment - emergent adverse event ( TEAE ) and 65 ( 61.3 % ) patients experienced at least 1 drug - related TEAE .", "label": "", "metadata": {}, "score": "56.30436"}
{"text": "The following safety endpoints were evaluated : incidence of adverse events ( AEs ) and serious AEs ( SAEs ) , vital signs , hematology , clinical chemistry , and urinalysis parameters , oropharyngeal examinations , and withdrawals due to worsening asthma .", "label": "", "metadata": {}, "score": "56.442127"}
{"text": "The pulmonary function tests ( PFTs ) were performed at each visit to the clinic in accordance with standard procedure , prior to study drug intake and at least 12 hours after the previous evening dose and 6 hours after the previous salbutamol dose .", "label": "", "metadata": {}, "score": "56.557003"}
{"text": "The primary outcome was the change in morning peak expiratory flow ( PEF ) rate from baseline to the end of the treatment period ( mean of weeks 23 - 24 ) .", "label": "", "metadata": {}, "score": "56.56231"}
{"text": "Results from this phase III study provide information on the longer - term effects of FF / VI on a number of clinically meaningful safety and tolerability endpoints such as UC excretion , ocular changes and heart rate .", "label": "", "metadata": {}, "score": "56.58454"}
{"text": "PubMed View Article .Clearie KL , Jackson CM , Fardon TC , Williamson PA , Vaidyanathan S , Burns P , Lipworth BJ : Supervised step - down of inhaled corticosteroids in the community - an observational study .", "label": "", "metadata": {}, "score": "56.615273"}
{"text": "van Noord JA , Aumann JL , Janssens E , Smeets JJ , Verhaert J , Disse B , Mueller A , Cornelissen PJ : Comparison of tiotropium once daily , formoterol twice daily and both combined once daily in patients with COPD .", "label": "", "metadata": {}, "score": "56.77041"}
{"text": "PubMed View Article .Meltzer EO , Korenblat PE , Weinstein SF , Noonan M , Karafilidis J : Efficacy and safety evaluation of ciclesonide in mild - to - moderate persistent asthma previously treated with inhaled corticosteroids .", "label": "", "metadata": {}, "score": "56.869522"}
{"text": "b Based on TNM Classification , 6 th edition .c The best overall tumor response during the induction therapy phase .This was used as the stratification factor for randomization to one of the maintenance phase arms .", "label": "", "metadata": {}, "score": "57.046436"}
{"text": "Statistical analysis .A within - subject variability of 191 mL ( estimated from a previous study ) and a sample size of 36 subjects would ensure the half - width of the 95 % CI for the treatment difference was no larger than 88 mL. Approximately 42 subjects were to be randomised to achieve 36 completed subjects ( assuming a 10 % failure rate ) .", "label": "", "metadata": {}, "score": "57.15037"}
{"text": "Study drug was supplied daily by blinded , third party study personnel to maintain blinding of patients and investigators .The primary efficacy variable was trough forced expiratory volume in one second ( FEV 1 ) at 24 h post - dose after 14 days .", "label": "", "metadata": {}, "score": "57.182877"}
{"text": "The lung function values were measured during the last visit .a the mean of the last 4 weeks of treatment derived from diary cards , b in the last 4 weeks of the treatment period .", "label": "", "metadata": {}, "score": "57.264923"}
{"text": "PubMed .Nelson JA , Strauss L , Skowronski M , Ciufo R , Novak R , McFadden ER : Effect of long - term salmeterol treatment on exercise - induced asthma .", "label": "", "metadata": {}, "score": "57.269535"}
{"text": "Safety .On - treatment AEs were similar between the study arms , with any AE being reported in 39 % of subjects during the placebo treatment period , in 43 % of subjects during the FF 100 treatment period , and in 35 % of subjects during the FF / VI 100/25 treatment period .", "label": "", "metadata": {}, "score": "57.269966"}
{"text": "The daytime asthma symptom score assessed the symptoms : shortness of breath , chest discomfort , wheezing , and cough over the previous 24 hour period on a scale of 0(no symptoms ) to 4(marked discomfort ) .", "label": "", "metadata": {}, "score": "57.347015"}
{"text": "All patients were assessed and treated on an out - patient basis .The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines and was approved by local ethics committees and institutional review boards as appropriate .", "label": "", "metadata": {}, "score": "57.394596"}
{"text": "The proportion of patients who reported any AE during the treatment period was 28 % in the placebo group and 31 - 39 % in the FF treatment groups .", "label": "", "metadata": {}, "score": "57.456192"}
{"text": "PubMed View Article .van den Berge M , Luijk B , Bareille P , Dallow N , Postma DS , Lammers JW : Prolonged protection of the new inhaled corticosteroid fluticasone furoate against AMP hyperresponsiveness in patients with asthma .", "label": "", "metadata": {}, "score": "57.48676"}
{"text": "A median of 4 cycles of maintenance therapy was delivered in each arm .Patients achieved a median OS of 13.9 months from randomization ( 16.9 months from start of induction ) on the pemetrexed continuation maintenance arm compared to 11.0 months from randomization ( 14.0 months from start of induction ) on the placebo arm [ 14 ] .", "label": "", "metadata": {}, "score": "57.497337"}
{"text": "During the study , 69 , 71 , and 61 % of subjects reported using salbutamol in the placebo , FF 100 and FF / VI 100/25 treatment periods , respectively , and 69 % reported salbutamol use during the washout periods .", "label": "", "metadata": {}, "score": "57.551403"}
{"text": "PubMed View Article .Claxton AJ , Cramer J , Pierce C : A systematic review of the associations between dose regimens and medication compliance .", "label": "", "metadata": {}, "score": "57.623585"}
{"text": "Any missing ACQ-6 scores at weeks 13 and 25 were imputed using the last observation carried forward method .A sensitivity analysis was performed after excluding subjects with missing ACQ-6 scores at weeks 13 and 25 .", "label": "", "metadata": {}, "score": "57.63202"}
{"text": "All spirometry assessments for each subject were performed at the same time of day ( \u00b1 1 hour ) and in the same manner .Between three and eight forced expiratory efforts were made at each session and the maximum FEV 1 of the two best efforts was recorded .", "label": "", "metadata": {}, "score": "57.64521"}
{"text": "Percentage of Patients With at Least 5 % Weight Loss From Baseline at Week 24 [ Time Frame : Baseline , Week 24 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "57.69651"}
{"text": "Pemetrexed is generally well tolerated ; however , its multiple enzyme inhibitions also account for the potentially adverse effects of pemetrexed , including myelosuppression ( mainly transient neutropenia ) , oral mucositis , diarrhea , and rash / desquamation .", "label": "", "metadata": {}, "score": "57.707924"}
{"text": "Due to the favorable results observed for switch maintenance therapy with pemetrexed , we conducted a randomized , phase 2 trial to examine the feasibility of continuation maintenance therapy with pemetrexed in patients with advanced , non - squamous NSCLC .", "label": "", "metadata": {}, "score": "57.804077"}
{"text": "Adherence with study treatment ( using the device dose counters ) was assessed throughout the treatment period .The central randomisation schedule was generated by the sponsor using a validated computerised system ( RandALL ; GlaxoSmithKline , UK ) .", "label": "", "metadata": {}, "score": "57.83985"}
{"text": "The primary , single , efficacy endpoint was the mean change from baseline at week 8 in the pre - dose ( morning or evening [ depending on regimen ] , pre - rescue bronchodilator ) FEV 1 ( measured using a MasterScope CT spirometer [ Viasys , Hoechberg , Germany ] ) .", "label": "", "metadata": {}, "score": "57.935814"}
{"text": "No significant differences between the groups were detected in any other parameter , including exacerbation frequency and adverse events .Conclusions .Stepping down patients whose asthma is controlled with the highest recommended dose of fluticasone / salmeterol to either 500/100 \u03bcg fluticasone / salmeterol daily or 400/24 \u03bcg extra - fine beclomethasone / formoterol daily provides comparable maintenance of lung function and asthma control .", "label": "", "metadata": {}, "score": "57.93688"}
{"text": "Weighted asthma exacerbation rate and the 95 % confidence interval ( CI ) were calculated as the total number of exacerbations / total duration of person - year follow - up .", "label": "", "metadata": {}, "score": "57.95344"}
{"text": "Discussion .This is the largest double - blind , placebo - controlled , dose - ranging study performed to date to determine whether an anti - IL-9 monoclonal antibody has any clinical benefits in subjects with poorly controlled , moderate - to - severe asthma .", "label": "", "metadata": {}, "score": "58.240513"}
{"text": "Patients .This study was carried out in 67 Respiratory Clinics in Europe .The study was performed in accordance with the Good Clinical Practice guidelines recommended by the International Conference on Harmonization of Technical Requirements .", "label": "", "metadata": {}, "score": "58.247887"}
{"text": "The efficacy and safety of switch maintenance therapy with pemetrexed has been examined in a previous randomized , double - blind , multinational , phase 3 study [ 5 ] .", "label": "", "metadata": {}, "score": "58.26097"}
{"text": "Symptoms and rescue medication use .The diurnal and nocturnal symptom scores were not different between the two groups at the end of the study , with neither group exhibiting a change from baseline ( Tables 2 , 3 ) .", "label": "", "metadata": {}, "score": "58.2797"}
{"text": "The patients in the FP / S group were treated with one inhalation twice daily ( daily dose 500 \u03bcg fluticasone/100 \u03bcg salmeterol ) .The patients in the BDP / F treatment group were treated with two inhalations twice daily ( daily dose 400 \u03bcg beclomethasone/24 \u03bcg formoterol ) .", "label": "", "metadata": {}, "score": "58.31334"}
{"text": "Change from baseline in pre - bronchodilator FEV 1 at week 25 was compared between placebo and MEDI-528 using a pair - wise t - test .", "label": "", "metadata": {}, "score": "58.38388"}
{"text": "PubMed View Article .Campbell LM , Watson DG , Venables TL , Taylor MD , Richardson PDI : Once daily budesonide turbohaler compared with placebo as initial prophylactic therapy for asthma .", "label": "", "metadata": {}, "score": "58.41365"}
{"text": "Sterling R , Lim J , Frith L , Snowise NG , Jacques L , Haumann B : Dose - related efficacy and optimal once - daily ( OD ) dosing interval of the long - acting beta2 agonist ( LABA ) , vilanterol trifenatate ( VI ) , in adults with persistent asthma .", "label": "", "metadata": {}, "score": "58.439266"}
{"text": "ADAs occurred in 4/82 subjects ( 4.9 % ) in the placebo group and 22/245 subjects ( 9.0 % ) in the MEDI-528 groups ( 30 mg : 15/81 , 18.5 % ; 100 mg : 4/83 , 4.8 % ; 300 mg : 3/81 , 3.7 % ) .", "label": "", "metadata": {}, "score": "58.492157"}
{"text": "For the incomplete - block design the within - patient variability is higher than that of a complete block design , and this therefore required a higher number of patients to be recruited .", "label": "", "metadata": {}, "score": "58.555046"}
{"text": "A total of 545 patients received one of five FF treatment groups and 101 patients received placebo ( intent - to - treat population ) .", "label": "", "metadata": {}, "score": "58.55942"}
{"text": "Only subjects who were taking medium- to high - dose ICS at screening were enrolled .Subjects who were uncontrolled while receiving medium - dose ICS were enrolled to the medium - dose or high - dose ICS group at the study physician 's discretion depending on their level of asthma control , and subjects receiving high - dose ICS were enrolled to the high - ICS group .", "label": "", "metadata": {}, "score": "58.81891"}
{"text": "N Engl J Med 1997 , 337 ( 20 ) : 1405 - 1411 .PubMed View Article .Foresi A , Mastropasqua B , Chetta A , D'Ippolito R , Testi R , Olivieri D , Pelucchi A : Step - down compared to fixed - dose treatment with inhaled fluticasone propionate in asthma .", "label": "", "metadata": {}, "score": "58.978817"}
{"text": "N Engl J Med 1997 , 337 : 1405 - 1411 .PubMed View Article .Suissa S , Ernst P , Benayoun S , Baltzan M , Cai B : Low - dose inhaled corticosteroids and the prevention of death from asthma .", "label": "", "metadata": {}, "score": "58.99735"}
{"text": "Conclusions .Indacaterol at doses of both 150 and 300 \u03bcg given once daily , resulted in clinically relevant 24-h bronchodilation with a fast onset of action in patients with moderate - to - severe COPD , and demonstrated a good overall safety and tolerability profile .", "label": "", "metadata": {}, "score": "59.018585"}
{"text": "All authors were involved in the drafting and revision of the manuscript .In addition , NM was involved in the study design and interpretation of the data .", "label": "", "metadata": {}, "score": "59.05128"}
{"text": "Finally , to commence each treatment period , subjects were required to exhibit an FEV 1 value within 10 % of the value exhibited at screening .", "label": "", "metadata": {}, "score": "59.067474"}
{"text": "Demographics and Baseline Characteristics ( intent - to - treat population ) .a 51 subjects took part in each of the treatment periods .Efficacy .", "label": "", "metadata": {}, "score": "59.139687"}
{"text": "View Article .Woodcock A , Bateman ED , Busse WW , L\u00f6tvall J , Snowise NG , Forth R , Jacques L , Haumann B , Bleecker ER : Efficacy in asthma of once - daily treatment with fluticasone furoate : a randomized , placebo - controlled trial .", "label": "", "metadata": {}, "score": "59.186756"}
{"text": "PubMed View Article .Berger WE , Kerwin E , Bernstein DI , Pedinoff A , Bensch G , Karafilidis J : Efficacy and safety evaluation of ciclesonide in subjects with mild - to - moderate asthma not currently using inhaled corticosteroids .", "label": "", "metadata": {}, "score": "59.267487"}
{"text": "DISEASE CHARACTERISTICS : .Histologically confirmed advanced solid tumor .Refractory disease .Patients must have been offered and refused OR received and failed prior treatment with all standard or approved therapies for the malignancy .", "label": "", "metadata": {}, "score": "59.34362"}
{"text": "PFS was measured from the date of randomization to the date of progression or death .For patients without documented disease progression who were not known to have died by the time of analysis , PFS was censored at the date of the last visit with adequate assessment .", "label": "", "metadata": {}, "score": "59.380863"}
{"text": "Only protocol deviations that were considered to affect efficacy were excluded from the efficacy analyses .The primary and secondary efficacy endpoints were analysed using a mixed - effects analysis of covariance ( ANCOVA ) model , with fixed effects of treatment , period , subject - level baseline , period - level baseline , country , sex and age and subject fitted as a random effect .", "label": "", "metadata": {}, "score": "59.489067"}
{"text": "This approach is rational when seeking to establish whether a novel intervention is capable of providing bronchoprotection , given the strong negative predictive power of the allergen challenge model [ 3 ] .", "label": "", "metadata": {}, "score": "59.508327"}
{"text": "Furthermore , FF 400 mcg once - daily dosing in the evening resulted in a similar improvement in pre - dose FEV 1 to FF 200 mcg twice daily .", "label": "", "metadata": {}, "score": "59.545967"}
{"text": "PubMed View Article .Donohue JF , Fogarty C , L\u00f6tvall J , Mahler DA , Worth H , Yorgancio\u011flu A , Iqbal A , Swales J , Owen R , Higgins M , Kramer B : Once - daily Bronchodilators for Chronic Obstructive Pulmonary Disease : Indacaterol versus Tiotropium .", "label": "", "metadata": {}, "score": "59.559826"}
{"text": "1186/\u200b2045 - 7022 - 2 - 11 ) contains supplementary material , which is available to authorized users .Background .The link between asthma and atopy is well established [ 1 ] .", "label": "", "metadata": {}, "score": "59.63365"}
{"text": "Mean increase from baseline in pre - bronchodilator FEV 1 was similar between the placebo and MEDI-528 groups at weeks 13 and 25 ( Figure 5 ) .", "label": "", "metadata": {}, "score": "59.640736"}
{"text": "Measuring HR 10 min post dose following FF / VI administration is an advantage as this permitted evaluation of the maximum potential effect of VI ( at the T max ) on HR .", "label": "", "metadata": {}, "score": "59.863274"}
{"text": "Placebo Comparator : Placebo .Placebo administered in this study was either a minimum of 0.008 mg / kg / IgE [ IU / mL ] every 2 weeks or a minimum of 0.016 mg / kg / IgE [ IU / mL ] every 4 weeks .", "label": "", "metadata": {}, "score": "59.865116"}
{"text": "Most AEs were mild or moderate in severity .One subject in the MEDI-528 100 mg group had a mild hypersensitivity reaction on the day of dosing that was considered possibly related to study medication and resolved the following day .", "label": "", "metadata": {}, "score": "59.86682"}
{"text": "Mean values for clinical chemistry parameters were similar across the treatment groups at screening and at Weeks 12 , 28 and 52 .No important safety concerns were reported for liver chemistry analyses .", "label": "", "metadata": {}, "score": "59.89351"}
{"text": "Vital signs .No clinically significant safety concerns were reported in systolic or diastolic blood pressure readings .Patients in the FF / VI groups had increases from baseline in mean pulse rate over clinic visits , whereas patients in the FP group generally had decreases from baseline in pulse rate .", "label": "", "metadata": {}, "score": "59.91456"}
{"text": "Ophthalmic assessments were completed by a qualified ophthalmologist at screening , Week 28 and Week 52 or early withdrawal .Examinations of posterior subcapsular opacity , cortical opacity , nuclear colour and nuclear opalescence were conducted using the Lens Opacities Classification System , Version III ( LOCS III ) .", "label": "", "metadata": {}, "score": "59.920082"}
{"text": "PubMed View Article .Bauwens O , Ninane V , Van de Maele B , Firth R , Dong F , Owen R , Higgins M : 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD : comparison with placebo and formoterol .", "label": "", "metadata": {}, "score": "59.999504"}
{"text": "PubMed View Article .Solomon B , Bunn PA Jr : Clinical activity of pemetrexed : a multitargeted antifolate anticancer agent .Future Oncol 2005 , 1 : 733 - 746 .", "label": "", "metadata": {}, "score": "60.05078"}
{"text": "Although not powered to show equivalence between the doses or scheduling of FF treatment , the results of this study indicate that FF dosed at 400 mcg once - daily in the evening resulted in similar efficacy to FF 200 mcg dosed twice - daily .", "label": "", "metadata": {}, "score": "60.090805"}
{"text": "FF at both doses and all regimens was generally well tolerated .FF 400 mcg administered once daily in the evening had similar efficacy to FF 200 mcg administered twice daily .", "label": "", "metadata": {}, "score": "60.124012"}
{"text": "The median number of ventricular ectopics ranged from 0 - 1 across the treatment groups .All events of NSVT and sustained supraventricular tachycardia resolved without treatment .", "label": "", "metadata": {}, "score": "60.1342"}
{"text": "PubMed View Article .Diette GB , Patino CM , Merriman B , Paulin L , Riekert K , Okelo S , Thompson K , Krishnan JA , Quartey R , Perez - Williams D , Rand C : Patient factors that physicians use to assign asthma treatment .", "label": "", "metadata": {}, "score": "60.19968"}
{"text": "Schatz M , Cook EF , Nakahiro R , Petitti D : Inhaled corticosteroids and allergy specialty care reduce emergency hospital use for asthma .J Allergy Clin Immunol 2003 , 111 : 503 - 508 .", "label": "", "metadata": {}, "score": "60.22242"}
{"text": "A ) Data are LSM \u00b1 SE .B ) Data are LSM \u00b1 SE .Safety .The overall incidence of AEs was similar across all treatments , and were predominantly mild or moderate in severity ( Table 3 ) .", "label": "", "metadata": {}, "score": "60.22908"}
{"text": "Statistical analysis .The study was not powered to formally assess differences between once - daily treatment and twice - daily treatment or differences between morning treatment and evening treatment , therefore statistical comparisons of all FF treatment groups were only against placebo .", "label": "", "metadata": {}, "score": "60.258934"}
{"text": "No significant difference was seen between the active treatments ( Table 2 ) .Table 2 .Statistical analysis a of treatment differences in change from post - saline baseline ( intent - to - treat population ) .", "label": "", "metadata": {}, "score": "60.270424"}
{"text": "All other authors were clinical investigators in the trial and were involved in patient care and data collection .All authors read and approved the final manuscript .", "label": "", "metadata": {}, "score": "60.35413"}
{"text": "Other exclusion criteria and prohibited medications are shown in the online supplementary material .All patients gave written informed consent .The study was approved by local ethics review committees and was conducted in accordance with the Declaration of Helsinki , Good Clinical Practice guidelines and all applicable regulatory requirements .", "label": "", "metadata": {}, "score": "60.41742"}
{"text": "No curative therapy available .PATIENT CHARACTERISTICS : .ECOG performance status 0 - 2 .Not pregnant .Two negative pregnancy tests required .Stable neurological exam .", "label": "", "metadata": {}, "score": "60.513744"}
{"text": "Sixty subjects in each treatment group would allow detection of a statistically significant difference between treatment groups with 58 - 99 % power based on a 2-sided type I error of 0.05 and 0.10 .", "label": "", "metadata": {}, "score": "60.542637"}
{"text": "In the current study , FF was generally well tolerated and the incidence of AEs with FF was low and generally similar to placebo ; however , three cases of oedema leading to withdrawal were reported with FF ( one in each of three different treatment groups ) .", "label": "", "metadata": {}, "score": "60.561493"}
{"text": "PubMed View Article .Molimard M , Martinat Y , Rogeaux Y , Moyse D , Pello JY , Giraud V : Improvement of asthma control with beclomethasone extrafine aerosol compared to fluticasone and budesonide .", "label": "", "metadata": {}, "score": "60.563602"}
{"text": "All subjects provided written informed consent before participating in the study .The protocol was approved by an Independent Ethics Committee at each study center , and the study was conducted in accordance with International Conference on Harmonisation Guidance for Good Clinical Practice and the Declaration of Helsinki .", "label": "", "metadata": {}, "score": "60.577473"}
{"text": "Level Less Than 7 % at Week 24 [ Time Frame : Week 24 ] [ Designated as safety issue : No ] .For a patient to be included in mITT population , both baseline and at least 1 post baseline assessment for at least 1 efficacy variable , were required .", "label": "", "metadata": {}, "score": "60.687927"}
{"text": "b Considered to be possibly drug - related .For the overall study period , 75/106 ( 70.8 % ) patients who received at least 1 dose of study drug experienced at least 1 TEAE , including 20 ( 71.4 % ) patients in the pemetrexed / BSC arm and 18 ( 66.7 % ) patients in the BSC arm .", "label": "", "metadata": {}, "score": "60.703697"}
{"text": "It is possible that the AEs on days 21 and 23 may have influenced the primary endpoint ; however , given the overall incidence of these events any effect would have been small .", "label": "", "metadata": {}, "score": "60.725975"}
{"text": "Five ( 17.9 % ) patients in the pemetrexed / BSC arm and 10 ( 37.0 % ) patients in the BSC arm were alive and progression - free at the end of the study .", "label": "", "metadata": {}, "score": "60.781082"}
{"text": "In a second study , budesonide 400 mcg administered once daily in the morning or evening was as effective as budesonide 200 mcg administered twice daily for 12 weeks .", "label": "", "metadata": {}, "score": "60.827305"}
{"text": "It is becoming increasingly apparent that asthma is a heterogeneous disease , and that identification of potential subgroups or individual subject characteristics is likely to be key in delivering optimal response with therapeutics such as MEDI-528 that target specific immunological mechanisms .", "label": "", "metadata": {}, "score": "60.902313"}
{"text": "Patients .Study participants had to be able to replace their current short - acting beta 2 agonist ( SABA ) therapy with salbutamol inhalation aerosol during the screening period , and to be able to withhold all inhaled short - acting beta sympathomimetic bronchodilators for 6 hours before each study visit .", "label": "", "metadata": {}, "score": "61.052048"}
{"text": "However , the response to inhaled allergen can be thought of as simulating the need to increase therapy , by experimentally destabilising asthma , and , therefore , mimicking a patient in need of ICS / LABA therapy .", "label": "", "metadata": {}, "score": "61.082436"}
{"text": "The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines .The study was approved by the ethics review board at each investigative site and all patients provided their written informed consent .", "label": "", "metadata": {}, "score": "61.105225"}
{"text": "Dose - related efficacy and optimal once - daily ( OD ) dosing interval of the long - acting beta 2 agonist ( LABA ) , vilanterol trifenatate ( VI ) , in adults with persistent asthma .", "label": "", "metadata": {}, "score": "61.12181"}
{"text": "PubMed View Article .Godard P , Greillier P , Pigearias B , Nachbaur G , Desfourgeres JL , Attali V : Maintaining asthma control in persistent asthma : comparison of three strategies in a 6-month double - blind randomised study .", "label": "", "metadata": {}, "score": "61.142525"}
{"text": "Not all subjects contributed data to all time points .Overall , significant attenuation of the EAR , as measured by all efficacy endpoints was observed with both treatments relative to placebo ( Table 2 ) .", "label": "", "metadata": {}, "score": "61.268196"}
{"text": "a the mean of the last 4 weeks of run - in period , b in each of the last 4 weeks of the run - in period .", "label": "", "metadata": {}, "score": "61.28064"}
{"text": "The reasons for screening failure and withdrawal were derived from the study termination form .Table 1 .Baseline characteristics of the patients examined , grouped based on randomised treatment .", "label": "", "metadata": {}, "score": "61.320393"}
{"text": "The secondary objective was to compare the effect of FF / VI 100/25 with that of FF 100 .These objectives were assessed through the primary endpoint of weighted mean ( wm ) change from post - saline baseline in FEV 1 between 0 - 2 h after the allergen challenge on treatment period Day 29 ( 22 - 23 h post - treatment on Day 28 ) .", "label": "", "metadata": {}, "score": "61.34121"}
{"text": "Inhaled rescue salbutamol use was permitted at any time , and oral corticosteroids were permitted only in the case of asthma exacerbation .No other anti - asthma medication was permitted at any time .", "label": "", "metadata": {}, "score": "61.389954"}
{"text": "a Missing mean ACQ score at Week 13 was imputed using the last observation carried forward method .b P - values are calculated using an analysis of covariance with treatment and baseline value as covariates .", "label": "", "metadata": {}, "score": "61.49055"}
{"text": "The EAR was also assessed using maximum percent decrease from post - saline baseline and minimum absolute FEV 1 ; the incidence of adverse events was a secondary endpoint .", "label": "", "metadata": {}, "score": "61.602623"}
{"text": "24-h urinary cortisol .UC measurements were available in 362 patients .Using information from the ITT population , the majority of patients had ' normal ' or ' no change ' from baseline in 24-h urine - free cortisol excretion at any post - baseline visit ( 76 - 81 % FF / VI ; 70 % FP ; table 3 ; see online supplementary figure S1 ) .", "label": "", "metadata": {}, "score": "61.62422"}
{"text": "Clinicaltrials.gov identifier : NCT01128569 , GSK Study number : HZA113090 .Keywords .Asthma Early allergic response ICS LABA Once - daily .Electronic supplementary material .", "label": "", "metadata": {}, "score": "61.62547"}
{"text": "These limitations may partly account for the lack of significant between - arm differences observed for the efficacy outcomes .Another potential limitation that could be worth mentioning is the absence of a placebo arm .", "label": "", "metadata": {}, "score": "61.739502"}
{"text": "Results .Similar PFS results were observed for the overall study period ( induction plus maintenance ) and when the PFS analysis was adjusted for sex , baseline disease stage , and the ECOG PS prior to randomization .", "label": "", "metadata": {}, "score": "61.76323"}
{"text": "However , in the once - daily mometasone furoate 200 mcg study , the change from baseline in FEV 1 and FVC with morning dosing was not significantly different from placebo [ 15 ] .", "label": "", "metadata": {}, "score": "61.7684"}
{"text": "Further , the efficacy results of this study support the results of the previous 26-week pivotal study conducted by Donohue et al [ 15 ] , in which tiotropium was administered on an open - label basis .", "label": "", "metadata": {}, "score": "61.82948"}
{"text": "Gibson PG , Powell H , Ducharme FM : Long - acting beta2-agonists as an inhaled corticosteroid - sparing agent for chronic asthma in adults and children .", "label": "", "metadata": {}, "score": "61.940067"}
{"text": "Previously it has been shown that a LABA / ICS combination resulted in significantly greater attenuation of the EAR compared to ICS alone [ 10 ] , although in that study , the challenge was not conducted at the end of the dosing interval .", "label": "", "metadata": {}, "score": "61.96096"}
{"text": "PubMed View Article .Rabe KF , Adachi M , Lai CK , Soriano JB , Vermeire PA , Weiss KB , Weiss ST : Worldwide severity and control of asthma in children and adults : the global asthma insights and reality surveys .", "label": "", "metadata": {}, "score": "61.986134"}
{"text": "Adjusted treatment ratio for 24-hour urinary cortisol excretion for each FF treatment group vs. placebo ( UC population ) .Error bars are 95 % confidence intervals .", "label": "", "metadata": {}, "score": "62.039204"}
{"text": "However , a 2 % incidence is not greater than the expected ( ' background ' ) rate of 1 - 3 % in healthy subjects .", "label": "", "metadata": {}, "score": "62.126743"}
{"text": "Twelve ( 11.3 % ) patients died during induction therapy .The observed toxicities were consistent with the known safety profile of the induction therapy regimen .", "label": "", "metadata": {}, "score": "62.16044"}
{"text": "Patient disposition .Baseline patient characteristics .Table 1 presents some key baseline characteristics for the randomized patients , before the start of induction therapy , and the patients ' best tumor response during the induction therapy phase .", "label": "", "metadata": {}, "score": "62.16919"}
{"text": "e One ( 0.9 % ) patient experienced grade 3 or 4 drug - related decreased appetite .f Six ( 5.7 % ) patients in the all treated patient population and 1 ( 3.6 % ) randomized patient in the pemetrexed / BSC arm experienced drug - related grade 3 or 4 anemia .", "label": "", "metadata": {}, "score": "62.250164"}
{"text": "Level Less Than or Equal to 6.5 % at Week 24 [ Time Frame : Week 24 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "62.284584"}
{"text": "Female patients of childbearing potential who were not using an acceptable method of contraception and patients with severe milk protein allergy or an adverse drug reaction to any beta 2 agonist , sympathomimetic drug or intranasal , inhaled , or systemic corticosteroid were also excluded .", "label": "", "metadata": {}, "score": "62.32479"}
{"text": "Mean HR at post - baseline visits were similar to screening and no increases were reported ; all groups had a slight decrease in HR with the greatest reduction reported on FP ( 5 bpm at Weeks 28 and 52 vs screening value ; table 4 ) .", "label": "", "metadata": {}, "score": "62.540504"}
{"text": "Asthma control during the run - in period and the treatment period ( raw means ) .BDP / F , beclomethasone dipropionate / formoterol ; FP / S , fluticasone propionate / salmeterol .", "label": "", "metadata": {}, "score": "62.54644"}
{"text": "FF 400 mcg once daily in the morning , although effective , resulted in a smaller improvement in morning pre - dose FEV 1 than FF 200 mcg twice daily at week 8 ( 315 ml vs. 202 ml ) .", "label": "", "metadata": {}, "score": "62.676292"}
{"text": "NGS was the clinical investigation leader , contributed to running the study and edited the manuscript .RF conducted statistical analysis of the data and edited the manuscript .", "label": "", "metadata": {}, "score": "62.706535"}
{"text": "Taking account of the incomplete block nature of the design , 126 evaluable patients would provide a power of 90 % for a one - sided test at the 1.25 % significance level ( half the usual alpha level to adjust for multiplicity ) .", "label": "", "metadata": {}, "score": "62.75067"}
{"text": "c Stratified for the best tumor response during the induction therapy and adjusted for sex , baseline disease stage ( before induction therapy ) , and the ECOG PS score before the initiation of maintenance therapy .", "label": "", "metadata": {}, "score": "62.876114"}
{"text": "FF / VI 100/25 and FF 100 both provided significant bronchoprotection against the EAR for all endpoints assessed .Both treatments were well tolerated .Conclusions .", "label": "", "metadata": {}, "score": "62.93345"}
{"text": "Th2 : .T helper cells .Declarations .Acknowledgements .The authors thank all subjects who consented to participate in this study , the study coordinators who facilitated the conduct of the study , and the following principal investigators .", "label": "", "metadata": {}, "score": "62.974197"}
{"text": "The LAR , when initiated by allergen challenge , is recognized as a valid clinical model of asthma , and has been widely employed to test the mechanism of the response [ 3 , 4 ] , and the efficacy of interventions [ 9 - 11 ] .", "label": "", "metadata": {}, "score": "63.013035"}
{"text": "J Thorac Oncol 2011 , 6 : 64 - 70 .PubMed .Therasse P , Arbuck SG , Eisenhauer EA , Wanders J , Kaplan RS , Rubinstein L , Verweij J , Van Glabbeke M , van Oosterom AT , Christian MC , Gwyther SG : New guidelines to evaluate the response to treatment of solid tumors .", "label": "", "metadata": {}, "score": "63.03042"}
{"text": "Discussion .Both FF / VI 100/25 and FF 100 clinically and significantly suppress the EAR to an allergen challenge relative to placebo .No major safety signals were observed in this crossover study , and in the one subject who discontinued due to an SAE , the event subsequently resolved .", "label": "", "metadata": {}, "score": "63.08946"}
{"text": "Furthermore , impaired lung function related to airway remodeling was reversed by IL-9 neutralization .Taken together , evidence from these and other experimental studies indicated that targeting IL-9 may offer a novel approach to the treatment of asthma .", "label": "", "metadata": {}, "score": "63.142105"}
{"text": "Eight ( 28.6 % ) patients in the pemetrexed / BSC arm , 12 ( 44.4 % ) patients in the BSC arm , and 38/106 ( 35.8 % ) patients from the entire study population experienced at least 1 grade 3/4 TEAE during the overall study period .", "label": "", "metadata": {}, "score": "63.179077"}
{"text": "Results .Patients .A total of 1424 patients were screened with 652 patients randomized into the study .A total of 646 randomized patients received at least one dose of study drug and comprised the ITT population .", "label": "", "metadata": {}, "score": "63.218628"}
{"text": "PubMed View Article .Fowler SJ , Currie GP , Lipworth BJ : Step - down therapy with low - dose fluticasone salmeterol combination or medium dose hydrofluoroalkane 134a - beclomethasone alone .", "label": "", "metadata": {}, "score": "63.256203"}
{"text": "FP 500 \u00b5g has been shown to improve lung function in patients with asthma and 500 \u00b5g twice daily is the highest recommended dosage for treating patients with asthma symptomatic on low - dose ICS .", "label": "", "metadata": {}, "score": "63.28379"}
{"text": "View Article PubMed .Kelly MM , O'Connor TM , Leigh R , Otis J , Gwozd C , Gauvreau GM , Gauldie J , O'Byrne PM : Effects of budesonide and formoterol on allergen - induced airway responses , inflammation , and airway remodeling in asthma .", "label": "", "metadata": {}, "score": "63.331856"}
{"text": "PubMed View Article .Vincken W , van Noord JA , Greefhorst AP , Bantje TA , Kesten S , Korducki L , Cornelissen PJ : Improved health outcomes in patients with COPD during 1 yr 's treatment with tiotropium .", "label": "", "metadata": {}, "score": "63.397865"}
{"text": "Kornmann O , Dahl R , Centanni S , Dogra A , Owen R , Lassen C , Kramer B : Once - daily indacaterol vs twice - daily salmeterol for COPD : a placebo - controlled comparison .", "label": "", "metadata": {}, "score": "63.419846"}
{"text": "Efficacy analyses , other than response - related analyses , were conducted using the qualified intent - to - treat ( Q - ITT ) analysis population , which consisted of all randomized patients .", "label": "", "metadata": {}, "score": "63.597633"}
{"text": "FF 200 mcg twice daily resulted in greater improvements in placebo - adjusted morning pre - dose FEV 1 than 400 mcg once daily in the morning at week 8 ( 315 ml vs. 202 ml ) .", "label": "", "metadata": {}, "score": "63.601933"}
{"text": "The TEAEs were graded according to the Common Terminology Criteria for Adverse Events ( CTCAE ) , version 3.0 .Statistical analysis .The primary objective of the study was to compare PFS for the maintenance therapy phase for pemetrexed / BSC vs BSC alone .", "label": "", "metadata": {}, "score": "63.620888"}
{"text": "EDB has served as a consultant to and received lecture fees from GlaxoSmithKline ; and his institution has received remuneration for participation in clinical trials sponsored by GlaxoSmithKline .", "label": "", "metadata": {}, "score": "63.64314"}
{"text": "EDB has served as a consultant to and received lecture fees from GlaxoSmithKline ; and his institution has received remuneration for participation in clinical trials sponsored by GlaxoSmithKline .", "label": "", "metadata": {}, "score": "63.64314"}
{"text": "At baseline , an average of 2.06 exacerbations / subject required oral steroids during the previous year .Abbreviations : ACQ-6 Asthma Control Questionnaire , AQLQ Asthma Quality of Life Questionnaire , BMI Body mass index , FEV 1 Forced expiratory volume in 1 second , FVC Forced vital capacity , ICS Inhaled corticosteroids , ITT Intent - to - treat .", "label": "", "metadata": {}, "score": "63.65133"}
{"text": "Corren et al . showed that lebrikizumab increased FEV 1 and reduced exacerbations in the high Th2 subgroup vs placebo [ 23 ] .Unfortunately , a pharmacodynamic marker for the IL-9 pathway has not been identified and IL-9 levels could n't be measured in blood or sputum in this study .", "label": "", "metadata": {}, "score": "63.696693"}
{"text": "Known history of drug or alcohol abuse within 6 months prior to the time of screening .Any clinically significant abnormality identified on physical examination , laboratory tests , electrocardiogram ( ECG ) or vital signs at the time of screening that in the judgment of the investigator or any sub - investigator precludes safe completion of the study or constrains efficacy assessment .", "label": "", "metadata": {}, "score": "63.801323"}
{"text": "10.1056/NEJM199807163390301 .View Article PubMed .Simons FE , Gerstner TV , Cheang MS : Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise - induced asthma using concurrent inhaled glucocorticoid treatment .", "label": "", "metadata": {}, "score": "63.853287"}
{"text": "Hence , given that our primary and secondary endpoints were PFS , OS and tumor response rate , we argue that the absence of a placebo would not introduce significant bias to our efficacy outcome measures in this trial .", "label": "", "metadata": {}, "score": "63.859993"}
{"text": "Due to the use of different inhalers to deliver the study drugs , patients were randomized not only to a treatment sequence , but also to a sequence of inhalers .", "label": "", "metadata": {}, "score": "63.86286"}
{"text": "There are a number of potential reasons for this observation .In the second instance , as the allergen challenge was conducted on Day 29 at trough drug levels , it is possible that any additional improvement in FEV 1 provided by VI through functional antagonism had abated at that time point .", "label": "", "metadata": {}, "score": "63.86291"}
{"text": "Exposure to aeroallergens may result in an EAR in sensitized individuals , which in turn may lead to symptoms and necessitate the use of rescue medication .", "label": "", "metadata": {}, "score": "63.88537"}
{"text": "Indacaterol has shown good overall safety and tolerability in clinical studies of up to 1-year duration with 24-h bronchodilator efficacy on once - daily dosing [ 12 - 17 ] .", "label": "", "metadata": {}, "score": "63.905838"}
{"text": "PubMed View Article .GOLD Report Executive Summary : Global Strategy for Diagnosis , Management , and Prevention of COPD .December 2009 .Santanello NC , Zhang J , Seidenberg B , Reiss TF , Barber BL : What are minimal important changes for asthma measures in a clinical trial ?", "label": "", "metadata": {}, "score": "63.923706"}
{"text": "The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose - limiting toxicity ( DLT ) .", "label": "", "metadata": {}, "score": "63.99726"}
{"text": "Headache was the most frequently reported AE ( Table 3 ) .AEs occurring at a frequency of greater than 3 % , and only in the active treatment arms , were : mouth ulceration and dysphonia , both of which occurred in 4 % of subjects with each active treatment .", "label": "", "metadata": {}, "score": "64.0657"}
{"text": "Authors ' contributions .CKO participated in design and coordination of the study .RL was a principal investigator for the study .KKM participated in the design of the study and interpretation of results .", "label": "", "metadata": {}, "score": "64.22577"}
{"text": "For a patient to be included in mITT population , both baseline and at least 1 post baseline assessment for at least 1 efficacy variable , were required .", "label": "", "metadata": {}, "score": "64.33318"}
{"text": "With placebo treatment , the greatest reduction in FEV 1 was observed between 15 and 30 min post challenge , from which point FEV 1 increased but had not returned to the post - saline baseline level at 120 min post challenge .", "label": "", "metadata": {}, "score": "64.38667"}
{"text": "PURPOSE : This phase I trial is studying the side effects and best dose of CC-4047 in treating patients with advanced solid tumors that did not respond to treatment .", "label": "", "metadata": {}, "score": "64.40173"}
{"text": "PubMed View Article .Rennard SI , Chapman KR , Luthra A , Swales J , Lassen C , Owen R , Kramer B : Once - daily indacaterol provides effective bronchodilation over 1 year of treatment in patients with chronic obstructive pulmonary disease ( COPD ) .", "label": "", "metadata": {}, "score": "64.40231"}
{"text": "PubMed View Article .Fardon T , Haggart K , Lee DK , Lipworth BJ : A proof of concept study to evaluate stepping down the dose of fluticasone in combination with salmeterol and tiotropium in severe persistent asthma .", "label": "", "metadata": {}, "score": "64.406975"}
{"text": "Three ( 10.7 % ) patients required red blood cell transfusions and 1 ( 3.6 % ) patient was hospitalized due to NSCLC .Four ( 14.3 % ) patients in the pemetrexed / BSC arm and 2 ( 7.4 % ) patients in the BSC arm died during the maintenance phase .", "label": "", "metadata": {}, "score": "64.59111"}
{"text": "Suissa S , Ernst P , Kezouh A : Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma .Thorax 2002 , 57 : 880 - 884 .", "label": "", "metadata": {}, "score": "64.61968"}
{"text": "PubMed View Article .Peters SP , Anthonisen N , Castro M , Holbrook JT , Irvin CG , Smith LJ , Wise RA , American Lung Association Asthma Clinical Research Centers : Randomized comparison of strategies for reducing treatment in mild persistent asthma .", "label": "", "metadata": {}, "score": "64.642586"}
{"text": "Rodrigo GJ , Neffen H , Catro - Rodriguez JA : Efficacy and safety of subcutaneous omalizumab vs placebo as add - on therapy to corticosteroids for children and adults with asthma .", "label": "", "metadata": {}, "score": "64.693695"}
{"text": "Background .Maintenance therapy for non - small cell lung cancer ( NSCLC ) aims to extend disease control after first - line chemotherapy with active and well - tolerated agents .", "label": "", "metadata": {}, "score": "64.77829"}
{"text": "Overall , all treatments in this study ( including placebo ) had good safety and tolerability profiles .The overall incidence of AEs was comparable across all treatment groups .", "label": "", "metadata": {}, "score": "64.81984"}
{"text": "PubMed View Article .Cazzola M , Matera MG , Lotvall J : Ultra long - acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease .", "label": "", "metadata": {}, "score": "64.839905"}
{"text": "Electrocardiogram ( ECG ) assessment ( heart rate [ HR ] and QTc[F ] , each measured 10 min post dose ) was completed at screening , at Weeks 2 , 12 , 28 and 52 or early withdrawal .", "label": "", "metadata": {}, "score": "64.9214"}
{"text": "PubMed View Article .Bateman ED , Jacques L , Goldfrad C , Atienza T , Mihaescu T , Duggan M : Asthma control can be maintained when fluticasone propionate / salmeterol in a single inhaler is stepped down .", "label": "", "metadata": {}, "score": "64.961685"}
{"text": "The placebo response has been well described in asthma studies and various explanations have been proposed .For example , Wise et al . reported that the placebo effect on asthma symptoms could be augmented by an optimistic message from the physician that enhanced the subject 's expectation of benefit from the drug [ 21 ] .", "label": "", "metadata": {}, "score": "64.96733"}
{"text": "The aim of this study was to compare the efficacy of an extra - fine beclomethasone / formoterol combination to that of a medium dose fluticasone / salmeterol combination in maintaining lung function and asthma control following a step - down in subjects whose asthma was controlled with a high dose ICS / LABA combination .", "label": "", "metadata": {}, "score": "65.02536"}
{"text": "Dent S , Zee B , Dancey J , Hanauske A , Wanders J , Eisenhauer E : Application of a new multinomial phase II stopping rule using response and early progression .", "label": "", "metadata": {}, "score": "65.05781"}
{"text": "Six weeks later , the subject was hospitalised .A diagnosis of histiocytic necrotising lymphadenitis ( Kikuchi 's Disease ) was made based on histology of an excised lymph node .", "label": "", "metadata": {}, "score": "65.07513"}
{"text": "Subject disposition and demographics .A total of 52 subjects were randomised and were included in the ITT population overall ; of these subjects , 51 took part in each of the treatment periods .", "label": "", "metadata": {}, "score": "65.15459"}
{"text": "The dose of placebo consisting of sucrose , L - histidine , L - histidine hydrochloride monohydrate , and polysorbate 20 was administered by subcutaneous injection every 2 or 4 weeks .", "label": "", "metadata": {}, "score": "65.16969"}
{"text": "2011 , 183 : A4488- .Subbarao P , Dorman SC , Rerecich T , Watson RM , Gauvreau GM , O'Byrne PM : Protection by budesonide and fluticasone on allergen - induced airway responses after discontinuation of therapy .", "label": "", "metadata": {}, "score": "65.28157"}
{"text": "Statistics .The study was designed to evaluate the equivalence of beclomethasone / formoterol treatment and fluticasone / salmeterol treatment after step - down .The primary efficacy variable was the change in morning PEF values from the baseline values to the end of the treatment period .", "label": "", "metadata": {}, "score": "65.3763"}
{"text": "Methods .In an incomplete - block , multi - dose , three - period , crossover design , patients received three of the following four treatments : indacaterol 150 \u03bcg , indacaterol 300 \u03bcg , tiotropium 18 \u03bcg and placebo , each once - daily for 14 days .", "label": "", "metadata": {}, "score": "65.39656"}
{"text": "Are pregnant or lactating .Have a known hypersensitivity to any ingredients of Xolair , including excipients ( sucrose , histidine , polysorbate 20 ) .", "label": "", "metadata": {}, "score": "65.449814"}
{"text": "Institutional Review Board or Independent Ethics Committee approval was obtained for each participating study center .All participants provided informed written consent prior to taking part in the study .", "label": "", "metadata": {}, "score": "65.55063"}
{"text": "Demographic and baseline characteristics of patients are summarized in Table 1 .Efficacy .For this endpoint , both doses of indacaterol not only met the criterion for non - inferiority compared with tiotropium , but also achieved numerically higher values , with differences versus tiotropium of 40 and 30 mL for indacaterol 150 and 300 \u03bcg , respectively , in the per - protocol population .", "label": "", "metadata": {}, "score": "65.57977"}
{"text": "PubMed View Article .Juniper EF , O'Byrne PM , Guyatt GH , Ferrie PJ , King DR : Development and validation of a questionnaire to measure asthma control .", "label": "", "metadata": {}, "score": "65.58896"}
{"text": "The reduction from baseline UC with FP was significantly different compared with FF / VI at Weeks 12 and 28 but not at Week 52 suggesting that UC excretion had recovered to pre - treatment levels in these patients ( UC population ) .", "label": "", "metadata": {}, "score": "65.84324"}
{"text": "Adverse events .The incidence of on - treatment AEs was similar across treatment groups ( 66 - 73 % ) , with headache , upper respiratory tract infection and nasopharyngitis the most frequently reported ( table 2 ) .", "label": "", "metadata": {}, "score": "65.8536"}
{"text": "SAEs were reported by 4 ( 4.9 % ) and 15 ( 6.1 % ) subjects in the placebo and combined MEDI-528 groups , respectively ( Table 4 ) .", "label": "", "metadata": {}, "score": "65.88083"}
{"text": "Two of these events ( angioedema and cerebrovascular accident , already described ) met the criteria for an SAE .No deaths were reported during the study .", "label": "", "metadata": {}, "score": "65.96224"}
{"text": "PubMed View Article .Andersson N , K\u00e4ll\u00e9n A , Thorsson L : A randomized controlled assessment of the effects of different dosing regimens of budesonide on the HPA - axis in healthy subjects .", "label": "", "metadata": {}, "score": "65.96379"}
{"text": "PubMed .Reddel HK , Gibson PG , Peters MJ , Wark PA , Sand IB , Hoyos CM , Jenkins CR : Down - titration from high - dose combination therapy in asthma : Removal of long - acting beta(2)-agonist .", "label": "", "metadata": {}, "score": "65.96846"}
{"text": "Conclusions .The present study demonstrated that 400/24 \u03bcg extra - fine BDP / F daily is equivalent to 500/100 \u03bcg FP / S daily in maintaining lung function and is comparable in maintaining asthma control in patients who were previously controlled with the highest recommended dose of FP / S ( 1000/100 \u03bcg daily ) .", "label": "", "metadata": {}, "score": "65.98675"}
{"text": "MH participated in study design and interpretation of results .NAM conceived the study and participated in its design and coordination .All authors have been involved in drafting the manuscript or revising it critically for important intellectual content , read , and approved the final manuscript .", "label": "", "metadata": {}, "score": "66.03958"}
{"text": "Summary of the FEV 1 time course of mean absolute FEV 1 from Day 1 pre - dose to 2 h post allergen challenge ( A ) and mean FEV 1 change from allergen challenge post - saline baseline measure ( B ) .", "label": "", "metadata": {}, "score": "66.157"}
{"text": "Two ISBCs were required for each daily study drug administration to each individual patient .The first ( unblinded ) ISBC ( who had no contact whatsoever with the patient ) prepared the study drugs and devices , maintained patient , investigator and the second ISBC blinding and ensured that the patients strictly adhered to their allocated drug sequence .", "label": "", "metadata": {}, "score": "66.15861"}
{"text": "All authors can vouch for the veracity and completeness of the data and data analysis .All authors read and approved the final manuscript .Authors ' Affiliations .", "label": "", "metadata": {}, "score": "66.29808"}
{"text": "Five patients in each arm experienced at least 1 grade 3/4 TEAE ( pemetrexed / BSC , 17.9 % ; BSC , 18.5 % ) and 1 patient in each arm experienced at least 1 SAE ( pemetrexed / BSC , 3.6 % ; BSC , 3.7 % ) .", "label": "", "metadata": {}, "score": "66.30328"}
{"text": "Randomization was stratified for baseline disease stage , the best overall response to the induction therapy , and the ECOG PS just prior to randomization [ 13 ] .", "label": "", "metadata": {}, "score": "66.34953"}
{"text": "PubMed View Article .Pavord ID , Korn S , Howarth P , Bleecker ER , Buhl R , Keene ON , Ortega H , Chanez P : Mepolizumab for severe eosinophilic asthma ( DREAM ) : a multicentre , double - blind , placebo - controlled trial .", "label": "", "metadata": {}, "score": "66.36526"}
{"text": "Eur Respir J 1997 , 10 : 815 - 821 .PubMed .Rossi A , Kristufek P , Levine BE , Thomson MH , Till D , Kottakis J , Della Cioppa G : Comparison of the efficacy , tolerability , and safety of formoterol dry powder and oral , slow - release theophylline in the treatment of COPD .", "label": "", "metadata": {}, "score": "66.36551"}
{"text": "Mean heart rate ( 24-h Holter monitoring ) decreased from screening values in all groups ( 0.2 - 1.1 bpm FF / VI vs 5 bpm FP ; Week 52 ) .", "label": "", "metadata": {}, "score": "66.38925"}
{"text": "The Gaining Optimal Asthma ControL study .Am J Respir Crit Care Med 2004 , 170 : 836 - 844 .PubMed View Article .Chung KF , Caramori G , Adcock IM : Inhaled corticosteroids as combination therapy with beta - adrenergic agonists in airways disease : present and future .", "label": "", "metadata": {}, "score": "66.454025"}
{"text": "PubMed View Article .Barnes PJ , Pedersen S , Busse WW : Efficacy and safety of inhaled corticosteroids .New developments .Am J Respir Crit Care Med 1998 , 157 : S1-S53 .", "label": "", "metadata": {}, "score": "66.46122"}
{"text": "Another study in a small number of subjects with mild - to - moderate asthma suggested that MEDI-528 may decrease sensitivity to exercise - induced bronchoconstriction that is dependent on mast cell degranulation [ 11 ] .", "label": "", "metadata": {}, "score": "66.62461"}
{"text": "If a female of childbearing potential , use an effective method of contraception ( in the opinion of the investigator ) to prevent pregnancy and agree to continue to practice an acceptable method of contraception for the duration of their participation in the study .", "label": "", "metadata": {}, "score": "66.635864"}
{"text": "A limitation of the present study is the open design which does not eliminate the possibility of patient and physician bias , even if the primary outcome was an objective lung function measure and data collection was independent of the investigator .", "label": "", "metadata": {}, "score": "66.71237"}
{"text": "PubMed View Article .J Allergy Clin Immunol 2009 , 124 : 436 - 438 .PubMed View Article .Bousquet J , Wenzel S , Holgate S , Lumry W , Freeman P , Fox H : Predicting response to omalizumab , an anti - IgE antibody , in patients with allergic asthma .", "label": "", "metadata": {}, "score": "66.80611"}
{"text": "Kim et al . demonstrated in Balb / c mice that cellular infiltration related to chronic airway inflammation and remodeling can be reduced by an anti - IL-9 antibody .", "label": "", "metadata": {}, "score": "66.808716"}
{"text": "Study treatment .Patients had stopped their usual ICS therapy one day prior to randomization .Patients who were randomized to once - daily treatment received a matching placebo Diskus \u00ae /Accuhaler \u00ae .", "label": "", "metadata": {}, "score": "66.820496"}
{"text": "FEV 1 , forced expiratory volume in 1 s .The mean trough FEV 1 values after treatment with both indacaterol 150 and 300 \u03bcg were numerically higher than with tiotropium , by 10 and 30 mL , respectively .", "label": "", "metadata": {}, "score": "66.833"}
{"text": "Weighted rate of asthma exacerbation ( 95 % CI ) at week 25 ( ITT population ) .Abbreviation : ITT , Intent - to - treat .", "label": "", "metadata": {}, "score": "66.834724"}
{"text": "More patients on FF / VI reported the AE of oral / oropharyngeal candidiasis than those receiving FP .However , the lower rate of oral / oropharyngeal candidiasis with FP versus FF / VI is not consistent with rates of this AE in other studies of FP when dosed at 500 \u00b5g twice daily .", "label": "", "metadata": {}, "score": "66.84967"}
{"text": "The PARAMOUNT study investigated whether pemetrexed continuation maintenance therapy would improve PFS after pemetrexed - cisplatin induction therapy in patients with advanced , non - squamous NSCLC [ 13 ] .", "label": "", "metadata": {}, "score": "66.93433"}
{"text": "Spirometry was used to assess FEV1 .All spirometry measurements were performed in accordance with the American Thoracic Society ( ATS ) guidelines .Omalizumab ( Xolair ) administered in this study was either a minimum of 0.008 mg / kg / IgE [ IU / mL ] every 2 weeks or a minimum of 0.016 mg / kg / IgE [ IU / mL ] every 4 weeks .", "label": "", "metadata": {}, "score": "66.98534"}
{"text": "Preclinical studies in animal models of asthma support a contributing role for an IL-9 mast cell axis in the immunopathology of asthma [ 5 ] .", "label": "", "metadata": {}, "score": "67.167076"}
{"text": "Another is that we did not include an active LABA comparator ; however current treatment guidelines 1 recommend against the use of LABA monotherapy in asthma due to a possible increased risk of severe exacerbation .", "label": "", "metadata": {}, "score": "67.21211"}
{"text": "In the last 5 years , PLP has received grants for educational activities and institutional research from AstraZeneca , Boehringer Ingelheim , Chiesi Farmaceutici S.p . A. , GlaxoSmithKline , Menarini , Merck Sharp & Dohme , Novartis , Nycomed , and Valeas .", "label": "", "metadata": {}, "score": "67.26825"}
{"text": "The numbers of patients with ECOG PS scores of 0 , 1 or 2 at the start of the maintenance phase were generally similar between the two maintenance arms ( 2 patients in each arm had an ECOG PS of 2 ; other data not reported here ) .", "label": "", "metadata": {}, "score": "67.31027"}
{"text": "Mean age of the study population overall was 45.1 years , with a higher proportion of females .More than half of the patients ( 57 % ) had at least a 10-year history of asthma and lung function was similar across all 6 treatment groups .", "label": "", "metadata": {}, "score": "67.52335"}
{"text": "Methods .Study design .This was a phase IIa , randomized , double - blind , parallel - group , placebo - controlled study conducted at 70 investigative sites in 16 countries around the world ( clinicaltrials.gov study number NCT00398645 ; GSK study number FFA106783 ) .", "label": "", "metadata": {}, "score": "67.533554"}
{"text": "Estimating an alpha error set to 0.05 ( two - sided ) , a standard deviation of 60 L / min and an expected difference between means equal to zero , a total of 191 patients were required in each group to have 90 % power to satisfy the above hypothesis .", "label": "", "metadata": {}, "score": "67.641525"}
{"text": "clinicaltrials.gov NCT00497237 .Keywords .Beclomethasone Extrafine Fluticasone Formoterol Salmeterol .Background .International guidelines recommend a stepwise approach for managing asthma in adults and children over 5 years of age [ 1 ] .", "label": "", "metadata": {}, "score": "67.64577"}
{"text": "Results .A total of 169 patients were randomized ( mean age 65 years ) ; 153 ( 90.5 % ) completed .For this endpoint , both doses of indacaterol not only met the criterion for non - inferiority compared with tiotropium , but also achieved numerically higher values , with differences versus tiotropium of 40 and 30 mL for indacaterol 150 and 300 \u03bcg , respectively .", "label": "", "metadata": {}, "score": "67.66106"}
{"text": "Studies with other monoclonal antibodies , including omalizumab [ 19 ] and mepolizumab [ 20 ] , also reported modest , if any , improvements in FEV 1 .", "label": "", "metadata": {}, "score": "67.704994"}
{"text": "PubMed View Article .Dahl R , Chung KF , Buhl R , Magnussen H , Nonikov V , Jack D , Bleasdale P , Owen R , Higgins M , Kramer B : Efficacy of a new once - daily LABA , indacaterol , versus the twice - daily LABA , formoterol , in COPD .", "label": "", "metadata": {}, "score": "67.7132"}
{"text": "A Randomized , Double - blind , Placebo - controlled , Parallel - group , Multicenter , 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 in Two Titration Regimens on Top of Metformin in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin .", "label": "", "metadata": {}, "score": "67.731575"}
{"text": "PubMed View Article .Baldwin CM , Perry CM : Pemetrexed : a review of its use in the management of advanced non - squamous non - small cell lung cancer .", "label": "", "metadata": {}, "score": "67.77459"}
{"text": "Proc Natl Acad Sci USA 1997 , 94 : 13175 - 13180 .PubMed View Article .Longphre M , Li D , Gallup M , Drori E , Ordonez CL , Redman T , Wenzel S , Bice DE , Fahy JV , Basbaum C : Allergen - induced IL-9 directly stimulates mucin transcription in respiratory epithelial cells .", "label": "", "metadata": {}, "score": "67.91566"}
{"text": "ITT : .Intent - to - treat .PEF : .Peak expiratory flow .SAE : .Serious adverse event .SD : .", "label": "", "metadata": {}, "score": "68.003006"}
{"text": "PubMed View Article .Pauwels RA , L\u00f6fdahl CG , Postma DS , Tattersfield AE , O'Byrne P , Barnes PJ , Ullman A : Effect of inhaled formoterol and budesonide on exacerbations of asthma .", "label": "", "metadata": {}, "score": "68.041595"}
{"text": "PubMed View Article .Thorax 2009 , 64 : 1025 - 1031 .PubMed View Article .Hermosa JL , S\u00e1nchez CB , Rubio MC , M\u00ednguez MM , Walther JL : Factors associated with the control of severe asthma .", "label": "", "metadata": {}, "score": "68.18541"}
{"text": "PubMed View Article .Corren J , Lemanske RF , Hanania NA , Korenblat PE , Parsey MV , Arron JR , Harris JM , Scheerens H , Wu LC , Su Z , Mosesova S , Eisner MD , Bohen SP , Matthews JG : Lebrikizumab treatment in adults with asthma .", "label": "", "metadata": {}, "score": "68.22107"}
{"text": "This study was funded by GlaxoSmithKline .We thank all patients who took part in the study and all of the investigators at the 45 centres .", "label": "", "metadata": {}, "score": "68.23429"}
{"text": "One patient experienced a clinically notable potassium value during treatment with tiotropium .Discussion .This randomized , double - blind study compared the 24-h spirometry profile of indacaterol 150 and 300 \u03bcg once - daily with that of tiotropium 18 \u03bcg once - daily and placebo in patients with moderate - to - severe COPD .", "label": "", "metadata": {}, "score": "68.30447"}
{"text": "Interpretation of these results should take into account the small numbers of subjects in some subgroups .The heterogeneous nature of asthma makes it difficult for a targeted therapy with monoclonal antibodies such as MEDI-528 to show significant beneficial effects in a non - selected asthma population .", "label": "", "metadata": {}, "score": "68.308975"}
{"text": "Oral candidiasis / oropharyngeal candidiasis was more common with FF / VI ( 6 - 7 % ) than FP ( 3 % ) .Twelve serious AEs were reported ; one ( worsening hepatitis B on FP ) was considered drug related .", "label": "", "metadata": {}, "score": "68.34877"}
{"text": "O'Byrne PM , Naya IP , Kallen A , Postma DS , Barnes PJ : Increasing doses of inhaled corticosteroids compared to adding long - acting inhaled beta2-agonists in achieving asthma control .", "label": "", "metadata": {}, "score": "68.37236"}
{"text": "PubMed View Article .Mintz M , Gilsenan AW , Bui CL , Ziemiecki R , Stanford RH , Lincourt W , Ortega H : Assessment of asthma control in primary care .", "label": "", "metadata": {}, "score": "68.48043"}
{"text": "The first study was a 7-day placebo - controlled dose ranging study , with an 8-day open - label tiotropium extension [ 13 ] .", "label": "", "metadata": {}, "score": "68.50423"}
{"text": "Inhaled corticosteroids ( ICS ) are recommended for patients with symptomatic asthma taking as - needed short acting bronchodilators .1 , 2 Long - acting \u03b2 2 agonists ( LABA ) are recommended in combination with ICS for patients who remain symptomatic on low - medium dose ICS alone . 1 - 3 The ICS , fluticasone furoate ( FF ) , together with the LABA , vilanterol ( VI ) , are in development as a novel , single - inhaler , once - daily ICS / LABA combination for asthma and chronic obstructive pulmonary disease .", "label": "", "metadata": {}, "score": "68.64583"}
{"text": "a Inhaled corticosteroids at stable dose : fluticasone / salmeterol ( 500 \u03bcg/50 \u03bcg or 250 \u03bcg/50 \u03bcg ) or budesonide / formoterol ( 160 \u03bcg/4.5 \u03bcg ) .", "label": "", "metadata": {}, "score": "68.67991"}
{"text": "Table 3 .Adverse events overall and by primary system organ class ( safety population ) .Primary system organ classes are sorted in descending order of frequency in the indacaterol 150 \u03bcg treatment .", "label": "", "metadata": {}, "score": "68.707466"}
{"text": "AO and JA coordinated data gathering and BvH collected data .CG led the statistical analysis .All authors vouch for the accuracy and completeness of the data and the data analysis .", "label": "", "metadata": {}, "score": "68.73274"}
{"text": "Abbreviations : ACQ-6 , Asthma Control Questionnaire-6 ; FEV 1 , Forced expiratory volume in 1 second ; s.c , Subcutaneous .Because MEDI-528 and placebo are visually distinct , study medication was administered at the clinic by unblinded personnel who were not otherwise involved in the study in order to maintain blinding .", "label": "", "metadata": {}, "score": "68.753044"}
{"text": "PubMed View Article .Jones TD , Crompton LJ , Carr FJ , Baker MP : Deimmunization of monoclonal antibodies .Methods Mol Biol 2009 , 525 : 405 - 423 .", "label": "", "metadata": {}, "score": "68.77922"}
{"text": "A total of 597 patients had no full protocol deviations and therefore comprised the PP population .Reasons for patient withdrawal at the screening and randomization stages are summarized in Figure 1 .", "label": "", "metadata": {}, "score": "68.78209"}
{"text": "It is of note that despite this , a low premature discontinuation rate was observed in this study .A crossover design ( rather than a parallel - group design ) was chosen because the within - patient variability in FEV 1 was expected to be less than between - patient variability with each patient acting as their own control .", "label": "", "metadata": {}, "score": "68.79553"}
{"text": "However , a separate study ( NCT01128595 ) investigating the effects of FF and VI alone and in combination on the EAR and LAR at 1 h post - dose in confirmed dual responders has been completed and will be reported elsewhere .", "label": "", "metadata": {}, "score": "68.938065"}
{"text": "Toxicity was assessed at baseline , before the start of each cycle ( during induction phase and maintenance phase in both arms ) , and approximately 30 days after the study therapy discontinuation .", "label": "", "metadata": {}, "score": "69.01785"}
{"text": "PubMed View Article .Pulm Pharmacol Ther 2007 , 20 : 740 - 749 .PubMed View Article .Rennard S , Bantje T , Centanni S , Chanez P , Chuchalin A , D'Urzo A , Kornmann O , Perry S , Jack D , Owen R , Higgins M : A dose - ranging study of indacaterol in obstructive airways disease , with a tiotropium comparison .", "label": "", "metadata": {}, "score": "69.07886"}
{"text": "PubMed View Article .Salter M , Biggadike K , Matthews JL , West MR , Haase MV , Farrow SN , Uings IJ , Gray DW : Pharmacological properties of the enhanced - affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease .", "label": "", "metadata": {}, "score": "69.14566"}
{"text": "Results .Patient disposition , demographics and baseline characteristics .A total of 211 patients were screened , 169 were randomized , and 153 ( 90.5 % ) completed .", "label": "", "metadata": {}, "score": "69.19197"}
{"text": "Methods .This was a prospective , randomised , controlled , two - arm parallel group study .Asthmatic patients who were fully controlled with a high daily dose ( 1000/100 \u03bcg ) of fluticasone / salmeterol were randomly assigned to 6 months of open - label treatment with either 500/100 \u03bcg fluticasone / salmeterol Diskus daily or 400/24 \u03bcg extrafine beclomethasone / formoterol pMDI daily .", "label": "", "metadata": {}, "score": "69.32431"}
{"text": "These reported observations support our hypothesis that targeting IL-9 via an anti - IL-9 mAb would be an effective treatment for patients with poorly controlled asthma .", "label": "", "metadata": {}, "score": "69.34665"}
{"text": "Treatment contrasts of trough FEV 1 ( L ) after 1 and 14 days of treatment ( mITT population ) .24-h post - dose ( trough ) FEV 1 ( L ) after 14 days of treatment ( mITT population ) .", "label": "", "metadata": {}, "score": "69.4091"}
{"text": "In a 12-week study , mometasone furoate 200 mcg administered once daily in the evening was more effective than mometasone furoate 200 mcg administered once daily in the morning in terms of change in FEV 1 and forced vital capacity ( FVC ) [ 15 ] .", "label": "", "metadata": {}, "score": "69.435814"}
{"text": "Following completion of the last treatment period , there was a follow - up period of 7 - 21 days .Allergen challenge .The subject - specific allergen was chosen based on the relative size of awheal reaction to cat hair , house dust mite and grass pollen allergens .", "label": "", "metadata": {}, "score": "69.55183"}
{"text": "10.1016/S0091 - 6749(98)70121 - 6 .View Article PubMed .Wong CS , Wahedna I , Pavord ID , Tattersfield AE : Effect of regular terbutaline and budesonide on bronchial reactivity to allergen challenge .", "label": "", "metadata": {}, "score": "69.63464"}
{"text": "PubMed View Article .Stassen M , Schmitt E , Bopp T : From interleukin-9 to T helper 9 cells .Ann N Y Acad Sci 2012 , 1247 : 56 - 68 .", "label": "", "metadata": {}, "score": "69.77074"}
{"text": "ADAs were detected in the placebo and all three MEDI-528 treatment groups .None of these events were considered to be serious , but it is unclear why ADAs were detected in the placebo group or in some subjects prior to administration of MEDI-528 .", "label": "", "metadata": {}, "score": "69.82164"}
{"text": "The proportion of subjects who reported at least one AE was similar between the placebo ( 68/82 , 82.9 % ) and MEDI-528 ( 30 mg : 62/81 , 76.5 % ; 100 mg : 68/83 , 81.9 % ; 300 mg : 69/81 , 85.2 % ) groups .", "label": "", "metadata": {}, "score": "69.83789"}
{"text": "Trial registration .ClinicalTrials.gov : NCT00615459 , EudraCT number : 2007 - 004071 - 19 .Background .According to the Global Initiative for Chronic Obstructive Lung Disease ( GOLD ) , inhaled bronchodilators , including \u03b2 2 -agonists and anticholinergics , are central to the symptomatic management of chronic obstructive pulmonary disease ( COPD ) [ 1 ] .", "label": "", "metadata": {}, "score": "69.8624"}
{"text": "Placebo Comparator : Placebo ( One - Step Titration ) .1-step initiation regimen of volume matching placebo : 10 mcg QD for 2 weeks , then 20 mcg QD up to the end of treatment .", "label": "", "metadata": {}, "score": "69.86417"}
{"text": "The study was powered for the key secondary objective , the non - inferiority comparison of indacaterol versus tiotropium for trough FEV 1 after 14 days , where a non - inferiority margin of 55 mL based on a Cochrane review [ 19 ] was adopted .", "label": "", "metadata": {}, "score": "69.95904"}
{"text": "PubMed View Article .Woolcock A , Rubinfeld AR , Seale JP , Landau LL , Antic R , Mitchell C , Rea HH , Zimmerman P : Thoracic Society of Australia and New Zealand , Asthma management plan .", "label": "", "metadata": {}, "score": "69.96381"}
{"text": "IL-9 induced the release of Th2-associated chemokines in cultured human airway smooth muscle cells [ 6 ] and enhanced the stem cell factor - dependent growth of human mast cell progenitors , particularly those from children with asthma [ 7 ] .", "label": "", "metadata": {}, "score": "69.99277"}
{"text": "White B , Leon F , White W , Robbie G : Two first - in - human , open - label , phase I dose - escalation safety trials of MEDI-528 , a monoclonal antibody against interleukin-9 , in healthy adult volunteers .", "label": "", "metadata": {}, "score": "70.03349"}
{"text": "ERB has served as a consultant to GlaxoSmithKline ; and has performed clinical trials for GlaxoSmithKline , which have been administered by his employer Wake Forest University Health Sciences .", "label": "", "metadata": {}, "score": "70.03496"}
{"text": "Results .No significant improvements in FEV 1 % predicted were observed between the placebo and MEDI-528 groups .Adverse events were comparable for placebo ( 82.9 % ) and MEDI-528 groups ( 30 mg , 76.5 % ; 100 mg , 81.9 % ; 300 mg , 85.2 % ) .", "label": "", "metadata": {}, "score": "70.155235"}
{"text": "Indacaterol may prove useful in patients with moderate - to - severe COPD , for whom treatment with one or more classes of long - acting bronchodilator is recommended .", "label": "", "metadata": {}, "score": "70.15721"}
{"text": "Differences between FF / VI and FP in adjusted mean change from baseline in QTc(F ) were -1.4 to 1.2 msec and none were statistically significant .", "label": "", "metadata": {}, "score": "70.23144"}
{"text": "Swystun VA , Bhagat R , Kalra S , Jennings B , Cockcroft DW : Comparison of 3 different doses of budesonide and placebo on the early asthmatic response to inhaled allergen .", "label": "", "metadata": {}, "score": "70.38811"}
{"text": "Tiotropium , the only currently available long - acting anticholinergic , has a duration of action of 24 h with once - daily dosing , and is effective in the long - term maintenance bronchodilator treatment of COPD [ 4 - 6 ] .", "label": "", "metadata": {}, "score": "70.41438"}
{"text": "Kim MS , Cho KA , Cho YJ , Woo SY : Effects of interleukin-9 blockade on chronic airway inflammation in murine asthma models .Allergy Asthma Immunol Res 2013 , 5 : 197 - 206 .", "label": "", "metadata": {}, "score": "70.5069"}
{"text": "Background .Fluticasone furoate ( FF ) is a novel long - acting inhaled corticosteroid ( ICS ) .Methods .The primary endpoint was mean change from baseline FEV 1 at week 8 in pre - dose ( morning or evening [ depending on regimen ] , pre - rescue bronchodilator ) FEV 1 .", "label": "", "metadata": {}, "score": "70.54549"}
{"text": "Overall , 5 ( 17.9 % ) patients in the pemetrexed / BSC arm and 3 ( 11.1 % ) patients in the BSC arm required red blood cell transfusions .", "label": "", "metadata": {}, "score": "70.56778"}
{"text": "Lipworth BJ : Systemic adverse effects of inhaled corticosteroid therapy : A systematic review and meta - analysis .Arch Intern Med 1999 , 159 : 941 - 955 .", "label": "", "metadata": {}, "score": "70.69525"}
{"text": "Conclusions .Once - daily indacaterol provided clinically and statistically significant 24-h bronchodilation .Indacaterol was at least as effective as tiotropium , with a faster onset of action ( within 5 min ) on the first day of dosing .", "label": "", "metadata": {}, "score": "70.806595"}
{"text": "A randomized , phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first - line treatment with pemetrexed and cisplatin for advanced , non - squamous , non - small cell lung cancer .", "label": "", "metadata": {}, "score": "70.96599"}
{"text": "History of metabolic acidosis , including diabetic ketoacidosis within 1 year prior to screening .Hemoglobinopathy or hemolytic anemia , receipt of blood or plasma products within 3 months prior to the time of screening .", "label": "", "metadata": {}, "score": "70.98897"}
{"text": "Primary and secondary outcomes .The primary efficacy outcome was change from baseline in mean ACQ-6 score at week 13 among individual MEDI-528 treatment groups and placebo .", "label": "", "metadata": {}, "score": "71.09122"}
{"text": "Endpoints .The incidence of adverse events ( AEs ) , serious AEs ( SAEs ) and severe asthma exacerbations were recorded throughout the study .", "label": "", "metadata": {}, "score": "71.10475"}
{"text": "An official American Thoracic Society / European Respiratory Society statement : asthma control and exacerbations : standardizing endpoints for clinical asthma trials and clinical practice .", "label": "", "metadata": {}, "score": "71.14743"}
{"text": "PubMed View Article .IMS Health - Retail Sales Data .Fabbri LM , Nicolini G , Olivieri D , Papi A : Inhaled beclometasone dipropionate / formoterol extra - fine fixed combination in the treatment of asthma : evidence and future perspectives .", "label": "", "metadata": {}, "score": "71.20586"}
{"text": "Table 2 .Efficacy measures for patients with non - squamous NSCLC by arm ( Pemetrexed + BSC vs BSC ) .a Two - sided 95 % confidence interval .", "label": "", "metadata": {}, "score": "71.2457"}
{"text": "Following randomisation , patients attended clinic during Weeks 2 , 4 , 8 , 12 , 20 , 28 , 36 , 44 and 52 .", "label": "", "metadata": {}, "score": "71.24823"}
{"text": "PubMed View Article .Gounni AS , Hamid Q , Rahman SM , Hoeck J , Yang J , Shan L : IL-9-mediated induction of eotaxin1/CCL11 in human airway smooth muscle cells .", "label": "", "metadata": {}, "score": "71.334465"}
{"text": "Gauvreau GM , Evans MY : Allergen inhalation challenge : a human model of asthma exacerbation .Contrib Microbiol .View Article PubMed .Grzelewska - Rzymowska I , Gondorowicz K , Cie\u015blewicz G , Rozniecki J : Course of non - specific bronchial reactivity to histamine after bronchospasm induced by allergen challenge in patients with bronchial asthma .", "label": "", "metadata": {}, "score": "71.36832"}
{"text": "The primary outcome measure was PFS from randomization .Secondary endpoints included : the overall response rate , the disease control rate , OS , one - year survival rates , and treatment - emergent adverse events .", "label": "", "metadata": {}, "score": "71.37117"}
{"text": "PubMed Central View Article PubMed .O'Byrne PM , Dolovich J , Hargreave FE : Late asthmatic response .Am Rev Respir Dis .10.1164/ajrccm/136.3.740 .", "label": "", "metadata": {}, "score": "71.4061"}
{"text": "All authors contributed equally to the development of the manuscript , and approved the final version for submission .Authors ' Affiliations .Universit\u00e4tsklinikum Gie\u00dfen und Marburg .", "label": "", "metadata": {}, "score": "71.45371"}
{"text": "The recruitment target was determined based on International Conference Harmonisation guidelines and feasibility considerations .Randomisation was planned for 200 patients to each FF / VI group , and 100 patients to the FP group .", "label": "", "metadata": {}, "score": "71.56051"}
{"text": "Study drugs were inhaled between 06:00 h and 10:00 h on each day throughout the treatment periods .Indacaterol and its matching placebo were made identical in appearance and were dispensed in such a manner so as to make them indistinguishable to patients and all blinded study personnel .", "label": "", "metadata": {}, "score": "71.62334"}
{"text": "Authors ' Affiliations .GlaxoSmithKline Respiratory and Immuno - Inflammation Medicines Development Centre .References .Eder W , Ege MJ , von Mutius E : The asthma epidemic .", "label": "", "metadata": {}, "score": "71.68118"}
{"text": "Study Type ICMJE .Interventional .Study Phase .Phase 1 .Study Design ICMJE .Endpoint Classification : Safety / Efficacy Study Intervention Model : Single Group Assignment Masking : Open Label Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "71.8134"}
{"text": "The LSM FEV 1 for indacaterol was numerically larger than for tiotropium at all timepoints for the 300 \u03bcg dose , and at a majority of timepoints for the 150 \u03bcg dose .", "label": "", "metadata": {}, "score": "71.89188"}
{"text": "The PEF values remained above 95 % of the predicted values throughout the study period ( Figure 2 ) .Conversely , no significant changes from baseline were detected in the PEF and FEV 1 or the PEF and FEV 1 % of predicted values that were measured in the standardised conditions of the clinic visits ( Table 3 ) .", "label": "", "metadata": {}, "score": "71.93051"}
{"text": "Bahadori K , Doyle - Waters MM , Marra C , Lynd L , Alasaly K , Swiston J , FitzGerald JM : Economic burden of asthma : a systematic review .", "label": "", "metadata": {}, "score": "72.04233"}
{"text": "PubMed .Cockroft DW : Airway hyperresponsiveness and late asthmatic responses .Chest .View Article .Gauvreau GM , Doctor J , Watson RM , Jordana M , O'Byrne PM : Effects of inhaled budesonide on allergen - induced airway responses and airway inflammation .", "label": "", "metadata": {}, "score": "72.08154"}
{"text": "Chest 2000 , 118 : 1294 - 1302 .PubMed View Article .Donohue JF , van Noord JA , Bateman ED , Langley SJ , Lee A , Witek TJ Jr , Kesten S , Towse L : A 6-month , placebo - controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol .", "label": "", "metadata": {}, "score": "72.114204"}
{"text": "PubMed View Article .Papi A , Paggiaro PL , Nicolini G , Vignola AM , Fabbri LM : Inhaled Combination Asthma Treatment versus SYmbicort ( ICAT SY ) Study Group .", "label": "", "metadata": {}, "score": "72.13492"}
{"text": "Experimental allergen challenge studies have shown the AR to comprise two temporal events , of which some subjects experience both while others experience only one [ 6 ] .", "label": "", "metadata": {}, "score": "72.154526"}
{"text": "PubMed View Article .J Allergy Clin Immunol 2000 , 105 : 108 - 115 .PubMed View Article .Oh CK , Raible D , Geba GP , Molfino NA : Biology of the interleukin-9 pathway and its therapeutic potential for the treatment of asthma .", "label": "", "metadata": {}, "score": "72.49626"}
{"text": "The frequency of SAEs was also similar across treatment groups .One SAE with FP ( worsening hepatitis B ) was considered by the investigator to be possibly treatment related .", "label": "", "metadata": {}, "score": "72.513336"}
{"text": "Use of the salbutamol Diskus \u00ae /Accuhaler \u00ae device or nebulized salbutamol ( excluding for reversibility testing during screening ) was not allowed during the study .", "label": "", "metadata": {}, "score": "72.56881"}
{"text": "Keywords .Asthma Anti - IL-9 monoclonal antibody MEDI-528 .Background .Asthma is a chronic inflammatory airway disease characterized by variable airflow limitation , airway hyperresponsiveness , mucus hypersecretion , and structural changes to the airways that include proliferation of smooth muscle [ 1 ] .", "label": "", "metadata": {}, "score": "72.59488"}
{"text": "Differences in the maximum absolute FEV 1 decrease from post - saline baseline between each active treatment and placebo were significant , but not significant between active treatments ( Table 2 ) .", "label": "", "metadata": {}, "score": "72.62652"}
{"text": "BDP / F , beclomethasone dipropionate / formoterol ; FP / S , fluticasone propionate / salmeterol ; BMI , body mass index ; FEV 1 , forced expiratory volume in 1 second ; PEF , peak expiratory flow .", "label": "", "metadata": {}, "score": "72.630035"}
{"text": "Ophthalmic assessments .No clinically significant differences between groups on the ophthalmic assessments of subcapsular opacity , cortical opacity , nuclear colour , nuclear opalescence , intraocular pressure or visual acuity were reported ( see online supplementary material for further details ) .", "label": "", "metadata": {}, "score": "72.639"}
{"text": "Additionally , to ensure that the handling of missing data did not lead to misinterpretation , the analysis was repeated using the main ANCOVA model adopting the expectation maximisation ( EM ) algorithm .", "label": "", "metadata": {}, "score": "72.64324"}
{"text": "Efficacy analysis was made on intention - to - treat ( ITT ) population including all subjects who had been randomised to treatment and had at least one recording after randomisation .", "label": "", "metadata": {}, "score": "72.68276"}
{"text": "Declarations .Acknowledgements .This study was funded by GlaxoSmithKline ( study number FFA106783 ; ClinicalTrials.gov identifier NCT00398645 ) .The article processing charge was paid for by GlaxoSmithKline .", "label": "", "metadata": {}, "score": "72.71301"}
{"text": "Abstract .Background .There is a need for preventative asthma maintenance therapy that provides lasting bronchoprotection against allergen provocation .Fluticasone furoate ( FF ) is a novel inhaled once - daily corticosteroid , being investigated as monotherapy for asthma and in combination with vilanterol ( VI ) , a novel inhaled once - daily long - acting beta - agonist , for asthma and chronic obstructive pulmonary disease .", "label": "", "metadata": {}, "score": "72.88394"}
{"text": "Concealed random allocation was done by using a fully automated functionality built into the electronic Case Report Form ( e - CRF ) .The study group was electronically assigned to any new patient by the system and was associated to a patient number with no possibility for the study staff of changing the random allocation .", "label": "", "metadata": {}, "score": "72.902626"}
{"text": "Eur Respir J 2007 , 29 : 682 - 689 .PubMed View Article .Papi A , Paggiaro P , Nicolini G , Vignola AM , Fabbri LM , ICAT SE study group : Beclomethasone / formoterol vs fluticasone / salmeterol inhaled combination in moderate to severe asthma .", "label": "", "metadata": {}, "score": "73.013275"}
{"text": "A computerized 12-lead ECG was recorded .Blood samples were collected for determination of the presence of anti - drug antibodies ( ADAs ) using an enzyme - linked immunosorbent or electrochemiluminescent assay [ 12 ] .", "label": "", "metadata": {}, "score": "73.09291"}
{"text": "Tabachnik E , Zadik Z : Diurnal cortisol secretion during therapy with inhaled beclomethasone dipropionate in children with asthma .J Pediatr 1991 , 118 : 294 - 297 .", "label": "", "metadata": {}, "score": "73.106064"}
{"text": "Pauwels RA , L\u00f6fdahl CG , Postma DS , Tattersfield AE , O'Byrne P , Barnes PJ , Ullman A : Effect of inhaled formoterol and budesonide on exacerbations of asthma .", "label": "", "metadata": {}, "score": "73.14557"}
{"text": "As with all allergen challenge studies , there were strengths and limitations associated with this study .The study was limited in that only effects on the EAR were investigated , and as patients were only assessed for the presence of the EAR at screening it is not possible to know how many of those recruited were single versus dual responders .", "label": "", "metadata": {}, "score": "73.16959"}
{"text": "Methods .This was a multinational , randomized , double - blind , double - dummy , placebo - controlled , multi - dose , Phase III , crossover study in patients with moderate - to - severe COPD .", "label": "", "metadata": {}, "score": "73.184814"}
{"text": "Plasma concentrations of FF and VI and derived pharmacokinetic parameters were reported , however , they are not presented in this manuscript .Statistical analysis .", "label": "", "metadata": {}, "score": "73.26315"}
{"text": "There were statistically significant improvements in pre - dose FEV 1 for each FF treatment arm compared with placebo ( Figure 2 , Table 2 ) .", "label": "", "metadata": {}, "score": "73.34883"}
{"text": "Maximum percentage change from post - saline baseline in FEV 1 over time is shown in Figure 3 , and the treatment differences between placebo , FF 100 and FF / VI 100/25 are summarised in Table 2 .", "label": "", "metadata": {}, "score": "73.37093"}
{"text": "OS was assessed using the Kaplan - Meier method .Between - arm comparisons were made using the log - rank test at a two - sided significance level of 0.05 .", "label": "", "metadata": {}, "score": "73.51483"}
{"text": "PubMed .Louahed J , Toda M , Jen J , Hamid Q , Renauld JC , Levitt RC , Nicolaides NC : Interleukin-9 upregulates mucus expression in the airways .", "label": "", "metadata": {}, "score": "73.59131"}
{"text": "Analysis of the primary efficacy endpoint was conducted using an analysis of covariance ( ANCOVA ) model with effects due to baseline pre - dose FEV 1 , country , sex , age , and treatment group .", "label": "", "metadata": {}, "score": "73.59247"}
{"text": "13601_2012_280_MOESM2_ESM.docx Additional file 2 : Supplement 2 .Change from allergen challenge post - saline baseline ( least squares means , 95 % CI ) for wmFEV 1 ( a ) , maximum % FEV 1 decline ( b ) and maximum absolute FEV 1 decline ( c ) .", "label": "", "metadata": {}, "score": "73.619316"}
{"text": "Authors ' contributions .PA , NG , CN , FLM , OD , RA and PPL All of the authors contributed to the study design , data interpretation and writing of the manuscript .", "label": "", "metadata": {}, "score": "73.64551"}
{"text": "A repeat dose , double - blind , placebo - controlled ' Thorough QT / QTc study ' to assess the cardiac safety of fluticasone furoate ( FF ) and vilanterol ( VI ) administered in combination .", "label": "", "metadata": {}, "score": "73.6568"}
{"text": "The study sponsor , MedImmune , was involved in the study design ; collection , analysis , and interpretation of data ; provided funding for writing support ; and approved the decision to submit the manuscript for publication .", "label": "", "metadata": {}, "score": "73.80002"}
{"text": "Therefore , it is possible that more patients in the BSC arm may have had a better general prognosis .Study design limitations include the small sample size and the randomization error , which resulted in patients being randomized to the pemetrexed / BSC and BSC arms in a 1:1 ratio rather than a 2:1 ratio .", "label": "", "metadata": {}, "score": "73.803665"}
{"text": "Conclusions .The addition of MEDI-528 to existing asthma controller medications was not associated with any improvement in ACQ-6 scores , asthma exacerbation rates , or FEV 1 values , nor was it associated with any major safety concerns .", "label": "", "metadata": {}, "score": "73.80835"}
{"text": "Abbreviations : ACQ-6 , Asthma Control Questionnaire-6 ; ITT , Intent - to - treat ; SE , Standard error .In addition , there was no difference between the steroid - stable and steroid reduction phases with regard to the effect of ICS and systemic steroids ( data not shown ) .", "label": "", "metadata": {}, "score": "74.00902"}
{"text": "All analyses were conducted using SAS \u00ae software version 9.1.3 ( SAS Institute Inc. , Cary , NC ) .Results .Patient disposition .Patient disposition is summarized in Figure 1 .", "label": "", "metadata": {}, "score": "74.01639"}
{"text": "PubMed View Article .Bateman ED , Boushey HA , Bousquet J , Busse WW , Clark TJ , Pauwels RA , Pedersen SE : GOAL Investigators Group .", "label": "", "metadata": {}, "score": "74.30327"}
{"text": "Detailed descriptions of all analyses and statistical tests used are provided in the online supplementary material .Results .Study population .A total of 503 patients were randomised ( ITT population ) ; 393 ( 78 % ) completed the study ( figure 1 ) .", "label": "", "metadata": {}, "score": "74.40024"}
{"text": "Choosing to participate in a study is an important personal decision .Talk with your doctor and family members or friends about deciding to join a study .", "label": "", "metadata": {}, "score": "74.52447"}
{"text": "Choosing to participate in a study is an important personal decision .Talk with your doctor and family members or friends about deciding to join a study .", "label": "", "metadata": {}, "score": "74.52447"}
{"text": "The values are the adjusted mean ( SE ) changes from baseline to the end of the study .BDP / F , beclomethasone dipropionate / formoterol ; FP / S , fluticasone propionate / salmeterol ; FEV 1 , forced expiratory volume in 1 second ; PEF , peak expiratory flow .", "label": "", "metadata": {}, "score": "74.53324"}
{"text": "PubMed View Article .van Noord JA , Smeets JJ , Custers FL , Korducki L , Cornelissen PJ : Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease .", "label": "", "metadata": {}, "score": "74.69472"}
{"text": "The most common reason for discontinuation was withdrawal of consent ( Figure 2 ) .Demographic characteristics were generally balanced between the groups ( Table 1 ) .", "label": "", "metadata": {}, "score": "74.8972"}
{"text": "No clinically significant effects on QTc(F ) outputs were observed during the study with FF / VI versus FP .Indeed , adjusted mean change from baseline in QTc(F ) with FF / VI 100/25 \u00b5g ranged from 1.2 to 5.7 FF / VI 200/25 \u00b5g and for FF 200/25 \u00b5g was -0.8 to 3.8 msec .", "label": "", "metadata": {}, "score": "74.93127"}
{"text": "PubMed View Article .Am J Respir Crit Care Med 2011 , 183 : 865 - 875 .PubMed View Article .Humbles AA , Reed JL , Parker J , Kiener PA , Molfino NA , Kolbeck R , Coyle AJ : Monoclonal antibody therapy directed against interleukin-9 : MEDI-528 .", "label": "", "metadata": {}, "score": "74.995514"}
{"text": "10.1016/j.jaci.2009.09.011 .View Article PubMed .Singh D , Petavy F , Macdonald AJ , Lazaar AL , O'Connor BJ : The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma .", "label": "", "metadata": {}, "score": "75.158134"}
{"text": "Key messages .What is the key question ?What is the bottom line ?Over 52 weeks , FF / VI ( 100/25 \u00b5g and 200/25 \u00b5g ) was well tolerated with an acceptable safety profile and there were no findings of significant clinical concern .", "label": "", "metadata": {}, "score": "75.20187"}
{"text": "Copyright .\u00a9 Woodcock et al ; licensee BioMed Central Ltd. 2011 .The purpose of this study is to evaluate the benefits and risks of lixisenatide ( AVE0010 ) , in comparison to placebo , as an add - on treatment to metformin , over a period of 24 weeks of treatment , followed by an extension .", "label": "", "metadata": {}, "score": "75.24715"}
{"text": "Comparison of AM and PM FEV 1 at week 8 following once - daily dosing in the evening or morning , or twice - daily dosing ( ITT population ) .", "label": "", "metadata": {}, "score": "75.29979"}
{"text": "Interest in IL-9 was first triggered by genetic linkage studies [ 2 ] and supported by the finding that expression of IL-9 and its associated receptor is higher in the airways of subjects with asthma compared with healthy controls [ 3 , 4 ] .", "label": "", "metadata": {}, "score": "75.69918"}
{"text": "10.1016/j.jaci.2004.11.023 .View Article PubMed .Parameswaran K , Inman MD , Watson RM , Morris MM , Efthimiadis A , Ventresca PG , Lam R , O'Byrne PM , Hargreave FE : Protective effects of fluticasone on allergen - induced airway responses and sputum inflammatory markers .", "label": "", "metadata": {}, "score": "75.89063"}
{"text": "For general information , see Learn About Clinical Studies .Please refer to this study by its ClinicalTrials.gov identifier : NCT00096954 Abstract .Background .Preclinical studies suggest that interleukin-9 may be a central mediator in the development and maintenance of airway inflammation in asthma .", "label": "", "metadata": {}, "score": "76.2625"}
{"text": "NCT00606021 .Keywords .Non - squamous Non - small cell lung cancer Pemetrexed Cisplatin Induction Maintenance .Background .In patients with advanced non - small cell lung cancer ( NSCLC ) , there is generally a brief period of disease control after response to first - line chemotherapy .", "label": "", "metadata": {}, "score": "76.35286"}
{"text": "PubMed .Chvetzoff G , Tannock IF : Placebo effects in oncology .J Natl Cancer Inst 2003 , 95 : 19 - 29 .PubMed View Article .", "label": "", "metadata": {}, "score": "76.51529"}
{"text": "Results .Subjects .Of the 329 randomized subjects , 327 received either placebo or MEDI-528 and were included in the ITT and safety populations .", "label": "", "metadata": {}, "score": "76.61432"}
{"text": "Edited by : Hansel TT , Barnes PJ .Basel : Karger ; 2010:137 - 140 .View Article .BMC Pulm Med 2011 , 11 : 14 .", "label": "", "metadata": {}, "score": "76.80609"}
{"text": "Methods .The primary endpoint was progression - free survival ( PFS ) from randomization , was analyzed using a Cox model , stratified for the tumor response at the end of induction therapy , at a one - sided alpha of 0.2 .", "label": "", "metadata": {}, "score": "77.004974"}
{"text": "The patient population for urinary cortisol ( UC ) analyses comprised all patients whose urine samples were not considered to have confounding factors that would affect the interpretation of the results .", "label": "", "metadata": {}, "score": "77.1031"}
{"text": "Donohue JF : Minimal clinically important differences in COPD lung function .COPD 2005 , 2 : 111 - 124 .PubMed View Article .Eur Respir J 2008 , 31 : 416 - 469 .", "label": "", "metadata": {}, "score": "77.10633"}
{"text": "In the BSC arm , 1 ( 3.7 % ) death was attributed to non - squamous NSCLC and 1 ( 3.7 % ) death was due to an AE ( cardiac arrest ) .", "label": "", "metadata": {}, "score": "77.13512"}
{"text": "Vilanterol ( VI ) , a novel inhaled once - daily LABA also exhibits efficacy and safety in persistent asthma [ 19 - 21 ] .", "label": "", "metadata": {}, "score": "77.317444"}
{"text": "NGS , RF , LJ and BH are employees of and hold stock / shares in GlaxoSmithKline .Authors ' contributions .All listed authors meet the criteria for authorship set forth by the International Committee for Medical Journal Editors .", "label": "", "metadata": {}, "score": "77.46825"}
{"text": "Declarations .Acknowledgements .This study was sponsored by Eli Lilly and Company , Indianapolis , IN , USA .The authors would like to thank all of the patients and investigative site staff who participated in the study .", "label": "", "metadata": {}, "score": "77.52315"}
{"text": "Eur Respir J 2005 , 26 : 319 - 338 .PubMed View Article .Barr RG , Bourbeau J , Camargo CA , Ram FS : Inhaled tiotropium for stable chronic obstructive pulmonary disease .", "label": "", "metadata": {}, "score": "77.52464"}
{"text": "PubMed View Article .Asmanex Twisthaler : Summary of product characteristics ( SPC ) .Mometasone furoate inhalation powder .Prim Care Respir J 2010 , 19 ( Suppl.1 ) : S1-S20 .", "label": "", "metadata": {}, "score": "77.693436"}
{"text": "10.1056/NEJMra054308 .View Article PubMed .O'Byrne PM : Allergen - induced airway inflammation and its therapeutic intervention .Allergy Asthma Immunol Res .", "label": "", "metadata": {}, "score": "77.94223"}
{"text": "Conclusions .FF at total daily doses of 200 mcg or 400 mcg was significantly more effective than placebo .FF 400 mcg once daily in the evening had similar efficacy to FF 200 mcg twice daily and all FF regimens had a safety tolerability profile generally similar to placebo .", "label": "", "metadata": {}, "score": "78.01718"}
{"text": "The unadjusted between - arm comparisons of PFS were conducted using a log rank test and a Wilcoxon test ( to account for early events ) .", "label": "", "metadata": {}, "score": "78.03336"}
{"text": "AW has served as consultant to Almirall , AstraZeneca , Chiesi , GlaxoSmithKline , Merck Sharpe and Dohme , Novartis and Schering Plough ; and has received research grants and travel expenses for attendance at ATS and ERS meetings from GlaxoSmithKline .", "label": "", "metadata": {}, "score": "78.158035"}
{"text": "Cox proportional hazards model , stratified for response at the end of the induction therapy ( CR and PR vs SD ) , was used to estimate the PFS HR .", "label": "", "metadata": {}, "score": "78.20144"}
{"text": "Data from preclinical studies provide strong evidence that an IL-9 mast cell axis regulates airway inflammation , mucus production , airway hyperresponsiveness , and subepithelial fibrosis , with increased IL-9 expression in the airways in humans with asthma [ 5 ] .", "label": "", "metadata": {}, "score": "78.22442"}
{"text": "FF has an ester derived from 2-furoic acid at the C-17\u03b1 position that replaces the simpler propionate ester [ 17 ] .This feature of FF confers both greater affinity for and longer retention in respiratory tissues than FP [ 18 ] .", "label": "", "metadata": {}, "score": "78.43494"}
{"text": "Exclusion Criteria : .At the time of screening age .Pregnant or breastfeeding women or women of childbearing potential with no effective contraceptive method .", "label": "", "metadata": {}, "score": "78.75775"}
{"text": "Equivalence was also confirmed with imputation of the missing primary efficacy variable data using the expectation maximisation algorithm , which showed a difference of 1.63 L / min between the BDP / F and FP / S groups ( 95 % CI , -14.49 to 17.76 ) .", "label": "", "metadata": {}, "score": "78.88783"}
{"text": "Authors ' contributions .DJ , SP , RO , MH and BK ( as employees of the study sponsor , Novartis ) contributed to the design , analysis and interpretation of the study , and oversaw its conduct .", "label": "", "metadata": {}, "score": "79.11529"}
{"text": "Study Arm ( s ) .Experimental : CC-4047 .Intervention : Drug : CC-4047 .Not Provided .Recruitment Information .Recruitment Status ICMJE .", "label": "", "metadata": {}, "score": "79.17851"}
{"text": "Although the most common AE in patients treated with indacaterol was cough , these events were mild or moderate in severity and were not associated with discontinuation from the study .", "label": "", "metadata": {}, "score": "79.334"}
{"text": "Study design .This was a prospective , randomised , controlled , multinational , multi - centre , open , two - arm parallel group study .", "label": "", "metadata": {}, "score": "79.63847"}
{"text": "Further information regarding the sample size estimation is provided in the online supplementary material .The intent - to - treat ( ITT ) population comprised all patients randomised to treatment who received at least one dose of study drug ( primary population for all data displays ) .", "label": "", "metadata": {}, "score": "79.64165"}
{"text": "Contributors All authors meet the criteria for authorship set forth by the International Committee for Medical Journal Editors , had full access to and interpreted the data , and wrote the manuscript .", "label": "", "metadata": {}, "score": "79.67353"}
{"text": "For general information , see Learn About Clinical Studies .Please refer to this study by its ClinicalTrials.gov identifier : NCT00763451 Publisher main menu .Follow BioMed Central .", "label": "", "metadata": {}, "score": "79.813385"}
{"text": "PubMed Central View Article PubMed .Cockcroft DW , Hargreave FE , O'Byrne PM , Boulet LP : Understanding allergic asthma from allergen inhalation tests .", "label": "", "metadata": {}, "score": "80.00886"}
{"text": "AR has received support for research and fees for consultations , travelling and speaking from AZ , GSK , BI , Pfizer , Chiesi Farmaceutici S.p . A. , Nycomed , and Philips .", "label": "", "metadata": {}, "score": "80.03495"}
{"text": "This article is published under license to BioMed Central Ltd.This was a multicenter , parallel - group , double - blind , randomized , placebo - controlled study that enrolled 333 subjects .", "label": "", "metadata": {}, "score": "80.71418"}
{"text": "Patients , investigators and study personnel were all blinded to study treatment .The central randomization schedule was generated by the sponsor using a validated computerized system ( RandAll ) .", "label": "", "metadata": {}, "score": "80.77455"}
{"text": "PubMed View Article .Biggadike K , Bledsoe RK , Hassell AM , Kirk BE , McLay IM , Shewchuk LM , Stewart EL : X - ray crystal structure of the novel enhanced - affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor - ligand binding domain .", "label": "", "metadata": {}, "score": "81.26306"}
{"text": "PubMed View Article .Koumis T , Samuel S : Tiotropium bromide : a new long - acting bronchodilator for the treatment of chronic obstructive pulmonary disease .", "label": "", "metadata": {}, "score": "81.81069"}
{"text": "Results for the PP population were consistent with those of the ITT population although the relative treatment effect of all FF treatment groups was generally lower .", "label": "", "metadata": {}, "score": "82.34367"}
{"text": "NIH Publication no : 07 - 4051 .Laszlo G : Standardisation of lung function testing : helpful guidance from the ATS / ERS Task Force .", "label": "", "metadata": {}, "score": "82.42496"}
{"text": "MedImmune .Department of Medicine , University of Calgary .Currently at KaloBios Pharmaceuticals , Inc .References .National Heart , Lung , and Blood Institute : National Asthma Education and Prevention Program : Guidelines for the diagnosis and management of asthma : expert panel report 3 , NIH Publication No . 07 - 4051 .", "label": "", "metadata": {}, "score": "82.56833"}
{"text": "Cardiovascular effects were more common on FF / VI 200/25 \u00b5g ( 18 % ) versus FF / VI 100/25 \u00b5g ( 12 % ) and FP ( 10 % ) due to extrasystoles reported on FF / VI 200/25 \u00b5g .", "label": "", "metadata": {}, "score": "82.73921"}
{"text": "[ P1168 ] , 204s .National Institutes of Health : Guidelines for the Diagnosis and Management of Asthma .National Institutes of Health National Heart , Lung and Blood Institute .", "label": "", "metadata": {}, "score": "83.04246"}
{"text": "JC was the study statistician .All authors vouch for the accuracy and completeness of the data and the data analysis .Funding The study was funded by GlaxoSmithKline .", "label": "", "metadata": {}, "score": "83.14693"}
{"text": "Given that an exact physical match to tiotropium was not available , a very difficult third - party blinded approach - probably the first of its kind - was employed in this study .", "label": "", "metadata": {}, "score": "83.303955"}
{"text": "Abbreviations : FEV 1 , Forced expiratory volume in 1 second ; ITT , Intent - to - treat ; SE , Standard error .Health - related quality of life .", "label": "", "metadata": {}, "score": "83.48633"}
{"text": "Acknowledgements .Susan Tomkins , a statistician from GlaxoSmithKline , was involved in the design and analysis plan for the study .Maurice Leonard , a former GSK employee , contributed to the design and played a key role in study set - up .", "label": "", "metadata": {}, "score": "83.54441"}
{"text": "This phase 2b , randomized , double - blind , placebo - controlled , parallel group study was conducted at 53 sites in North America , Central America , South America , and Asia between October 2009 and November 2011 .", "label": "", "metadata": {}, "score": "83.596436"}
{"text": "The mean subject age was 35.4 years , 35 % were female , and 92 % were of white race ( Table 1 ) .Ten subjects ( 19 % ) were challenged with cat dander / hair , 23 subjects ( 44 % ) with grass pollen , and 19 subjects ( 37 % ) with house dust mite .", "label": "", "metadata": {}, "score": "83.777374"}
{"text": "PubMed View Article .Barnes PJ , Belvisi MG , Mak JC , Haddad EB , O'Connor B : Tiotropium bromide ( Ba 679 BR ) , a novel long - acting muscarinic antagonist for the treatment of obstructive airways disease .", "label": "", "metadata": {}, "score": "84.04425"}
{"text": "The intent - to - treat ( ITT ) population , which included all randomized patients who received at least one dose of study medication , was the primary population for all efficacy and safety ( excluding urinary cortisol ) analyses .", "label": "", "metadata": {}, "score": "84.22454"}
{"text": "Gender .Both .Ages .18 Years and older .Accepts Healthy Volunteers .No .Contacts ICMJE .Contact information is only displayed when the study is recruiting subjects Abstract .", "label": "", "metadata": {}, "score": "84.319305"}
{"text": "L Andersen , L Apoux , JC and LJ are employees of and hold stock in GlaxoSmithKline .Ethics approval Local ethics review committees from the 45 centres involved in the study .", "label": "", "metadata": {}, "score": "84.356445"}
{"text": "Unadjusted , unstratified PFS for the maintenance phase ( from randomization ) for the Q - ITT analysis population .Unadjusted , unstratified OS for the maintenance phase ( from randomization ) for the Q - ITT analysis population .", "label": "", "metadata": {}, "score": "84.96747"}
{"text": "Enrollment ICMJE .Completion Date .August 2012 .Primary Completion Date .September 2010 ( final data collection date for primary outcome measure ) .", "label": "", "metadata": {}, "score": "86.63019"}
{"text": "PubMed .Matsuzawa S , Sakashita K , Kinoshita T , Ito S , Yamashita T , Koike K : IL-9 enhances the growth of human mast cell progenitors under stimulation with stem cell factor .", "label": "", "metadata": {}, "score": "86.67885"}
{"text": "PubMed Central PubMed .Johnston NW , Sears MR : Asthma exacerbations 1 : Epidemiology ( Review series ) .Thorax .10.1136/thx.2005.045161 .", "label": "", "metadata": {}, "score": "86.934586"}
{"text": "The dose of allergen used was determined during screening using an allergen challenge where subjects were required to inhale increasing doses of allergen using a dosimeter and the effect on FEV 1 was measured after each inhalation .", "label": "", "metadata": {}, "score": "86.98774"}
{"text": "J Natl Cancer Inst 2000 , 92 : 205 - 216 .PubMed View Article .Lung Cancer 2006 , 52 : 155 - 163 .", "label": "", "metadata": {}, "score": "87.024635"}
{"text": "Statistical Sciences Department , Eli Lilly Australia .References .J Clin Oncol 2011 , 29 : 3825 - 3831 .PubMed View Article .Coate LE , Shepherd FA : Maintenance therapy in advanced non - small cell lung cancer : evolution , tolerability and outcomes .", "label": "", "metadata": {}, "score": "87.212845"}
{"text": "PubMed View Article .European Respiratory Society 2010 .[ P1166 ] , 204s .European Respiratory Society 2010 .[ P1167 ] , 204s .", "label": "", "metadata": {}, "score": "87.36597"}
{"text": "Design .This was a multi - centre , randomised , double - blind , placebo - controlled , 3- period crossover study conducted at two sites in the UK , one in Germany and one in New Zealand .", "label": "", "metadata": {}, "score": "88.36134"}
{"text": "PubMed View Article .Masoli M , Fabian D , Holt S , Beasley R : Global Initiative for Asthma ( GINA )Program : The global burden of asthma : executive summary of the GINA Dissemination Committee report .", "label": "", "metadata": {}, "score": "88.75728"}
{"text": "PubMed Central View Article PubMed .Eur Respir J. 2012 , Feb 23 , ePub ahead of print .Am J Respir Crit Care Med .", "label": "", "metadata": {}, "score": "89.56146"}
{"text": "Acknowledgements .The authors thank the patients who took part and the staff at the participating clinical centres .The authors would like to thank Sam T Mathew , professional medical writer ( Novartis ) and David Young ( Novartis ) for assistance in the preparation of this manuscript .", "label": "", "metadata": {}, "score": "89.58896"}
{"text": "Background .Indacaterol is a novel , inhaled , once - daily , ultra - long - acting \u03b2 2 -agonist for the treatment of chronic obstructive pulmonary disease ( COPD ) .", "label": "", "metadata": {}, "score": "89.754074"}
{"text": "Chad Oh and Nestor Molfino were employed by MedImmune during the conduct of the study and owned stock in AstraZeneca .Micki Hultquist , Kimmie McLaurin , and Keunpyo Kim are employees of MedImmune and own stock in AstraZeneca .", "label": "", "metadata": {}, "score": "90.39699"}
{"text": "This study was funded by Chiesi Farmaceutici SpA , Parma , Italy .One of the authors ( GN ) is an employee of the sponsor and was involved with the study design , data interpretation and writing of the report .", "label": "", "metadata": {}, "score": "90.948364"}
{"text": "Allocation : Randomized Endpoint Classification : Efficacy Study Intervention Model : Parallel Assignment Masking : Double Blind ( Subject , Investigator )Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "91.35446"}
{"text": "Conclusions .This study was designed to further evaluate the clinical effects of MEDI-528 , an anti - IL-9 antibody , in light of the inconclusive results obtained in previous small studies .", "label": "", "metadata": {}, "score": "92.48317"}
{"text": "Benjamin van Hecke was employed by Hammersmith Research Ltd at the time of this study .Authors ' contributions .All listed authors meet the criteria for authorship set forth by the International Committee for Medical Journal Editors .", "label": "", "metadata": {}, "score": "92.50561"}
{"text": "Novartis Horsham Research Centre .Novartis Pharmaceuticals Inc. , One Health Plaza .References . global Initiative for Chronic Obstructive Lung Disease ( GOLD ) : Global strategy for the diagnosis , management , and prevention of chronic obstructive pulmonary disease .", "label": "", "metadata": {}, "score": "95.644394"}
{"text": "Study design .This was a multicenter , randomized , open - label , parallel - arm , phase 2 trial conducted at 8 investigative sites in 3 countries : Egypt , Lebanon , and Saudi Arabia .", "label": "", "metadata": {}, "score": "97.097565"}
{"text": "PubMed View Article .J Clin Oncol 2012 . , 30 ( suppl ; abstr LBA7507 ) : .Pre - publication history .Copyright .", "label": "", "metadata": {}, "score": "97.52747"}
{"text": "Authors ' Affiliations .Research Center on Asthma and COPD , University of Ferrara .Medical Affairs Department , Chiesi Farmaceutici .Department of Internal and Specialistic Medicine , Section of Respiratory Diseases , University of Catania .", "label": "", "metadata": {}, "score": "98.04679"}
{"text": "Competing interests .NM and ZL are full - time employees of Eli Lilly and Company , the manufacturer of pemetrexed .All other authors agree in declaring they have no competing interests ( RG , SS , TH , DA , HAA , GEH , and HAH ) .", "label": "", "metadata": {}, "score": "98.64726"}
{"text": "The intent - to - treat ( ITT ) population was defined as all randomized subjects who received either placebo or MEDI-528 .The safety population included all subjects who received either placebo or MEDI-528 and had safety data .", "label": "", "metadata": {}, "score": "99.116234"}
{"text": "View Article .Copyright .\u00a9 Papi et al . ; licensee BioMed Central Ltd. 2012 .This article is published under license to BioMed Central Ltd.", "label": "", "metadata": {}, "score": "99.320816"}
{"text": "View Article PubMed .Thorax .View Article PubMed .Eur Respir J. 2010 , 36 ( Suppl 54 ) : 204s- .Resp Med .", "label": "", "metadata": {}, "score": "99.75289"}
{"text": "10.1542/peds.99.5.655 .View Article PubMed .Eur Respir J. 2003 , 21 : 1050 - 1068 .View Article PubMed .Copyright .\u00a9 Oliver et al . ; licensee BioMed Central Ltd. 2012 .", "label": "", "metadata": {}, "score": "100.330536"}
{"text": "Lancet 2009 , 374 : 1432 - 1440 .PubMed View Article .Lancet Oncol 2012 , 13 : 292 - 299 .PubMed View Article .", "label": "", "metadata": {}, "score": "101.10853"}
{"text": "PubMed View Article .Copyright .\u00a9 Vogelmeier et al .2010 .This article is published under license to BioMed Central Ltd.", "label": "", "metadata": {}, "score": "101.26111"}
{"text": "This study was funded by Novartis Pharma AG , Basel , Switzerland .Damon Jack , Simon Piggott , Roger Owen , Mark Higgins , Benjamin Kramer are employees of Novartis .", "label": "", "metadata": {}, "score": "101.80101"}
{"text": "Medical Department , Eli Lilly and Company , Middle East and North Africa .Medical Oncology Department , National Cancer Institute , Cairo University .Clinical Oncology Department , Assiut University Cancer Centre .", "label": "", "metadata": {}, "score": "101.84856"}
{"text": "Brazil : E Fiss , C Fritscher , J Hetzel , E Pizzichini , R Stelmach .Canada : J Hebert , M Fitzgerald , R Olivenstein , I Mayers , A Cheema , W Yang .", "label": "", "metadata": {}, "score": "106.03136"}
{"text": "Copyright .\u00a9Oh et al . ; licensee BioMed Central Ltd. 2013 .This article is published under license to BioMed Central Ltd.Affiliated with .", "label": "", "metadata": {}, "score": "106.17465"}
{"text": "Cancer Center Department , Middle East Institute of Health .Clinical Oncology Department , Kasr El - Einy Cancer Institute , Cairo University .Clinical Oncology Department , Faculty of Medicine , Alexandria University .", "label": "", "metadata": {}, "score": "106.31278"}
{"text": "Authors ' original submitted files for images .Below are the links to the authors ' original submitted files for images .Competing interests .Amanda Oliver , Caroline Goldfrad and Jonathan Ayer are shareholders and employees of GlaxoSmithKline .", "label": "", "metadata": {}, "score": "108.67895"}
{"text": "Department of Medicine , University of Cape Town .Department of Medicine , University of Wisconsin .Center for Genomics and Personalized Medicine , Wake Forest University Health Sciences Winston - Salem .", "label": "", "metadata": {}, "score": "108.732086"}
{"text": "Acknowledgements .The following investigators ( sites ) were involved in the FORTE study .Spain : Serra Batlles Jose ( Vic ) .Bulgaria : Rositza Dimitrova ( Veliko Tarnovo ) , Georgi Hinkov ( Sofia ) , Vladimir Asenov Hodzhev ( Plovdviv ) , Dimo Mitev Dimov ( Stara Zagora ) , Hristo Metev Metev ( Ruse ) and Troshanova Evelina ( Burgas ) .", "label": "", "metadata": {}, "score": "113.89981"}
{"text": "Costa Rica : T Mitchell .Panama : L Noriega .Peru : A Matsuno , C Villaran , J Portugal , O Cubas .Philippines : T Aquino , T Atienza , R Samoro .", "label": "", "metadata": {}, "score": "116.419136"}
